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THE EUKARYOTIC SMC5/6 COMPLEX REPRESSES THE REPLICATIVE 
PROGRAM OF HIGH-RISK HUMAN PAPILLOMAVIRUS 
 
Human papillomaviruses (HPVs) are non-enveloped, circular double-stranded 
DNA viruses that infect basal keratinocytes of stratified squamous epithelia. 
High-risk HPV (HR-HPV) infection causes nearly all cervical cancers and an 
increasing number of head and neck cancers. While prophylactic vaccinations 
have reduced the incidence of HPV infection and attributable cancers, currently 
there is no cure for pre-existing HPV infection. As such, HPV remains a global 
health threat and a better understanding of HPV biology remains of significant 
medical importance for identification of novel therapeutic targets. 
 
The multi-subunit structural maintenance of chromosomes 5/6 complex (SMC5/6) 
is comprised of SMC5, SMC6 and NSE1-4. SMC5/6 is essential for homologous 
recombination DNA repair and reportedly functions as an antiviral factor during 
hepatitis B and herpes simplex-1 viral infections. Intriguingly, SMC5/6 has been 
found to associate with HR-HPV E2 proteins, which are multifunctional 
transcription factors essential to regulation of viral replication and transcription. 
The function of SMC5/6 associations with E2, as well as its role during HR-HPV 
infection remain unclear and we explored this question in the context of HR-HPV-
31. SMC6 interacted with HPV-31 E2 and co-immunoprecipitation of SMC6/E2 
vii 
complexes required the E2 transactivation domain, inferring SMC6 association is 
limited to the full-length E2 isoform. Depletion of SMC6 and NSE3 increased 
HPV replication and transcription in keratinocytes stably maintaining episomal 
HPV-31, suggesting that the SMC5/6 complex represses these processes. 
Neither SMC6 nor NSE3 co-IP the viral E1 DNA helicase alone or E1/E2 
complexes but the association of SMC6 with E2 was reduced in the presence of 
E1, indicating that SMC6 competes with E1 for E2 binding. This infers that SMC6 
repression of the viral replicative program may involve inhibiting initiation of viral 
replication by disrupting E2 interactions with E1. Chromatin immunoprecipitation 
determined that SMC6 is present on episomal HPV-31 genomes, alluding to a 
possible role for SMC5/6 in modifying the chromatin state of viral DNA. Taken 
together, these findings describe a novel function for SMC5/6 as a repressor of 
the HPV-31 replicative program. 
 
Elliot Androphy, MD (Chair) 
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Papillomaviruses (PVs) are non-enveloped, double-stranded circular DNA 
viruses belonging to the viral Papillomaviridae family. The Papillomaviridae family 
of viruses are amongst the most ancient of viral families, believed to have 
evolved approximately 450 million years ago [1]. PVs infect basal keratinocytes 
of the skin and mucosal epithelium and are transmitted horizontally when 
microabrasions compromise the integrity of the epithelial layers, enabling PV 
access to basal keratinocytes [2]. Human papillomaviruses (HPVs) represent the 
most extensively studied of PVs, however, 53 different genera of PVs have been 
identified and shown to infect multiple different animals with a species-restricted 
tropism [3]. Indeed, a variety of primates, birds, reptiles, and most recently fish 
have all been found to be infected by PVs [4]. 
 
1.1.1 Human Papillomaviruses 
 
While over 53 different genera of PVs have been identified, only 5 genera (alpha, 
beta, gamma, mu, nu) are known to infect humans [5]. To date, roughly 200 
different types of HPVs have been discovered and are classified within these 
genera based on nucleotide sequence similarity of the viral L1 gene [6]. Of the 
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five genera shown to infect humans, certain genera are considered to be “low-
risk” (LR-HPVs) and others “high-risk” (HR-HPVs) based on their oncogenic 
potential (Table 1.1). LR-HPVs typically infect the cutaneous epithelia and 
demonstrate minimal carcinogenic potential, and as such LR-HPV infections 
usually only result in benign lesions (papillomas). HPVs belonging to the beta, 
gamma, mu, and nu genera are generally considered by the International Agency 
for Research on Cancer (IARC) to be low-risk, however, data increasingly 
suggests that beta PVs may play a role as co-carcinogens in the development on 
non-melanoma skin cancer [7]. Certain alpha HPVs (HPV-6, -11) also fall within 
the low-risk categorization, as infection with these mucosotropic HPVs can result 
in benign genital lesions but fail to progress towards malignancy. Twelve 
mucosotropic HPVs belonging to the alpha genera are classified as carcinogenic 
and referred to as high-risk HPVs (HR-HPVs), as these HR-HPVs have been 
shown to be etiological agents in multiple different cancers, such as cervical, 
anal, penile, and oropharyngeal cancers [8]. Of the HR-HPVs, HPV-16 and HPV-
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Table 1.1. HPV genotypes and genera classified based on oncogenic risk. 
HPV Type Genera Tropism Oncogenic Risk 
HPV-3 beta cutaneous epithelia low 
HPV-5 beta cutaneous epithelia low 
HPV-6 alpha mucosal epithelia low 
HPV-8 beta cutaneous epithelia low 
HPV-11 alpha mucosal epithelia low 
HPV-16 alpha mucosal epithelia high 
HPV-18 alpha mucosal epithelia high 
HPV-31 alpha mucosal epithelia high 
HPV-33 alpha mucosal epithelia high 
HPV-35 alpha mucosal epithelia high 
HPV-39 alpha mucosal epithelia high 
HPV-45 alpha mucosal epithelia high 
HPV-51 alpha mucosal epithelia high 
HPV-52 alpha mucosal epithelia high 
HPV-56 alpha mucosal epithelia high 
HPV-58 alpha mucosal epithelia high 
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1.1.2 Epidemiology 
 
HPVs are the most common sexually transmitted human pathogens [10]. 
Infection with either LR- or HR-HPVs belonging to the alpha genera is believed to 
primarily occur through horizontal transmission via sexual exposure of a 
susceptible individual with an HPV-positive partner. As such, roughly 90% of 
individuals are estimated to become infected with a sexually transmitted HPV 
during their lifetime [11]. Globally, HPV prevalence is highest early in life at 
roughly 25 years of age and decreases as age increases [12]. The majority of 
infected individuals remain asymptomatic and clear the viral infection within 1 to 
2 years [12, 13]. However, in those individuals that fail to clear infections, chronic 
HR-HPV infection can progress towards malignancy. While less frequent, vertical 
transmission of HPV is known to occur, however the extent of the long-term risks 
associated with mother-to-infant transmission remain unclear [14-16].  
 
Despite the availability of highly effective prophylactic HPV vaccinations the need 
to vaccinate early in life, low uptake, public mistrust, as well as preclusive 
barriers in the global implementation of vaccination programs have allowed for 
HPV to persist as a significant medical pathogen. Epidemiological data support 
that HR-HPV remains a leading cause of cancers worldwide, causing roughly 5% 
of all cancers globally (nearly 630,000 cases annually) and accounting for nearly 
30% of cancer cases attributed to infectious agents in both men and women [9, 
17]. The majority of HPV-related cancers are diagnosed in women and the 
   5 
highest global burden occurs in less developed, lower-income regions of the 
world [9, 18] (Figure 1.1). Currently, no curative treatment exists for those with 
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Figure 1.1. Global HPV prevalence. Rough age-specific global and regional 
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1.1.3 Prevention 
 
The most effectual means of preventing HPV-related disease is by blocking initial 
infection through the use of prophylactic vaccines. Currently, 3 vaccines are 
available and all are made using recombinant viral-like particles (VLPs) 
comprised of the HPV major capsid protein, L1 [19]. L1 has been shown to 
spontaneously self-assemble into icosahedral capsids that are identical in size 
and structure to the native HPV virion [20-24] and are highly immunogenic 
[21](Figure 1.2). As such, each VLP-based vaccine has demonstrated greater 
than 90% efficacy in preventing infection by the HPV types for which they are 
indicated [25-27] (Table 1.2). While highly effective at preventing infection there 
is no therapeutic benefit in administering the vaccine to previously infected 
individuals [28-30]. As such, the WHO and CDC recommend vaccination of both 
girls and boys early in life, as well as later for individuals not previously 
vaccinated (CDC, 2016).  
 
   8 
 
 
Figure 1.2. HPV-16 L1 VLP reconstructed by cryo-EM. HPV-16 L1 viral-like 
particle (VLP) reconstructed by cryo-EM when calculated at 18 Å. This image 
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Table 1.2. FDA-licensed HPV vaccines. 
VACCINE HPV L1 TYPE PRODUCER CELL 
FDA 
LICENSURE 
Cervarix -16, -18 
Trichoplusia ni (Hi 5) 
insect cell 
2009 
Gardasil -6, -11, -16, -18 
Saccharomyces 
cerevesiae yeast cell 
2006 
Gardasil 9 
-6, -11, 16, -18, -31, 
-33, -45, -52, -58 
Saccharomyces 
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1.2 High-Risk HPV Genome 
 
HPVs possess a closed, circular double-stranded DNA genome roughly 8 
kilobases in size that is maintained as an episome in the nuclei of infected 
keratinocytes [32] (Figure 1.3). The viral genome is comprised of three primary 
regions: the long control region (LCR), early region, and late region [7]. The LCR 
contains the viral origin of replication (ori), enhancer and silencer sequences, 
early promoter, HPV E1 and E2 protein binding sites, as well as sites necessary 
for the binding of various cellular factors involved in regulating replication and 
transcription of the viral genome [33]. A late promoter located downstream of the 
LCR in the E7 ORF is only activated upon keratinocyte differentiation in the later 
stages of the viral life cycle [34]. The early region contains 6 of the 8 HPV open 
reading frames (ORFs) which are transcribed from the early promoter located 
upstream of the viral E6 gene. These ORFs encode for the 6 viral proteins 
designated as early (E) (E1, E2, E4, E5, E6, E7). With the exception of E4, the 
descriptor of E was assigned due to their expression throughout the viral life 
cycle. E4 was termed an early protein due to the location of the E4 ORF being 
within the early region of the viral genome amongst the true viral early proteins 
[35]. However, E4 is only detected in the later stages of the viral life cycle and no 
early functions have been confirmed. The true early proteins (E1, E2, E5, E6, E7) 
execute multiple functions during the viral life cycle, such as regulating 
transcription and replication, immune evasion and maintaining infected cells in a 
proliferative state [36]. The late region encodes the HPV late (L) proteins (L1, L2) 
   11 
that encapsidate viral genomes in the outer layers of the epithelium prior to 
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Figure 1.3. HPV-31 genome. The HPV-31 genome is roughly 8 kb in length and 
encodes for 8 viral proteins transcribed from viral early (pE) and late (pL) 
promoters and terminated at early (poly(A)E) or late (poly(A)L) polyadenylation 
sequences. The viral LCR contains the keratinocyte-specific enhancer, putative 
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1.2.1 Viral Proteins 
 
The 8 proteins encoded by HPV perform multiple functions that enable 
completion of the viral life cycle. Protein expression is tightly regulated based on 
the phase of the viral replicative program and state of keratinocyte differentiation. 
Aside from categorization as early or late, the viral proteins can be further 
segregated by function; the replicative proteins (E1, E2), oncogenic proteins (E5, 
E6, E7), structural (capsid) proteins (L1, L2), and the less well understood E4 
protein, which is believed to play a role in genome amplification [37-40] and 
potentially in the production of infectious virions [35]. While the E1 DNA helicase 
and E2 transcription factor are sufficient for transient viral replication [41-43], 
stable replication also requires E6 and E7 oncoproteins [44, 45]. The temporal 
control of viral protein expression prevents over-amplification of viral genomes 
and the expression of the highly immunogenic L1 capsid protein that could 
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1.2.2 HPV E1 
 
The viral E1 ATP-dependent DNA helicase is the most highly conserved protein 
among PVs and only encoded protein to possess enzymatic activity, belonging to 
the superfamily III (SF3) family of AAA+ (ATPases Associated with various 
cellular Activities) helicases [46].  E1 is essential for PV replication throughout 
the viral life cycle, being required for the initial replication and establishment of 
viral infection, replicative maintenance, and amplification of viral genomes. 
Additionally, E1 may also play a role in HPV infection by modulating host-gene 
expression to inhibit the host anti-viral response [47].  
 
Structurally, E1 is comprised of 3 functional regions, an N-terminal regulatory 
region (NRR), DNA-binding domain and C-terminal enzymatic domain [46] 
(Figure 1.4). The NRR is essential for E1-mediated viral replication in vivo and 
contains the E1 nuclear localization (NLS) and export (NES) signals. 
Phosphorylation of the NLS and NES regulate E1 nucleocytoplasmic shuttling 
[48-54]. The DNA-binding domain of E1 functions to recognize the viral ori and 
E1 binding sites adjacent the viral ori but has been shown to demonstrate poor 
specificity [46]. The C-terminal domain of E1 contains the oligomerization 
domain, Walker A/B ATPase domain needed for catalyzing ATP hydrolysis and 
the unwinding of DNA, and C-terminal brace. The C-terminal brace functions in 
the stabilization and assembly of E1 hexamers [55]. Both the DNA-binding 
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domain and C-terminal enzymatic domains have been shown to be essential for 
























Figure 1.4. HPV E1.  (Top) The N-terminal regulatory region of E1 (NRR- green) 
contains the viral nuclear localization signals (NLS). The DNA-binding domain 
(blue) recognizes E1 binding sites in the viral genome LCR region. The 
enzymatic region (purple) of E1 consists of an oligomerization domain (O), 
ATPase domain and C-terminal brace. (Bottom) Crystal structure of the PV E1 
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E1 initiates viral replication through both its helicase activity and interactions with 
cellular replication factors [46] (Figure 1.5). The initiation of bi-directional viral 
DNA replication requires recruitment of E1 to the viral ori by E2, as the poor 
specificity for E1 DNA-binding precludes efficient viral replication in the absence 
of the enhanced specificity provided by E2 [58-62]. E2-mediates E1 recruitment 
to the viral ori by binding the C-terminal helicase domain (HD) of E1 using the E2 
TAD [63-67], then directing it to the viral ori via the E2 DNA-binding domain [46]. 
E2 binding to the E1 HD also serves to inhibit non-specific binding of E1 with 
cellular DNA [68, 69]. Following E2-mediated recruitment of E1 to the viral LCR, 
the E1 DBD binds E1BS adjacent to the viral ori, for which a transient E1/E2-
DNA ternary complex is formed prior to the release of E2 from the complex and 
viral genome [46, 70-73]. E1 then forms a double-trimer and hydrolyzes ATP, 
which opens the viral ori, displaces E2, and allows for the formation of the E1 
double hexamer [71, 73-76]. E1 hexamers then proceed to bi-directionally 
unwind viral DNA using ATP hydrolysis. During this process E1 also recruits host 
factors needed for replicating viral genomes, such as DNA polymerase α-primase 
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Figure 1.5. HPV replication initiation. HPV E1 is recruited to the viral ori and 
then form a double-trimer. Initial unwinding of the viral ori via ATP-hydrolysis 
causes displacement of E2 and the assembly of the E1 double-hexamer. Double-
hexamers proceed to unwind DNA bi-directionally and E1 mediates recruitment 
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1.2.3 HPV E2 
 
E2 is an essential multifunctional 40 kDa transcription factor that is expressed 
throughout the viral life cycle [79]. It is the primary factor involved in regulating 
viral replication and transcription [59, 69, 80]. E2 is also required for the 
maintenance and equal partitioning of viral genomes to daughter cells following 
cell division [81-85]. Lacking intrinsic enzymatic activity E2 is reliant upon 
interactions with viral proteins and a multitude of host factors (Table A.1) to 
execute its functions during the viral life cycle [79].  
 
Structurally, monomeric full-length E2 is comprised of an N-terminal 
transactivation domain (TAD) that is connected to its C-terminal DNA-binding 
domain (DBD) by a disordered hinge region [86-91] (Figure 1.6). Both the TAD 
and DBD of E2 are relatively well conserved across different PVs, however the 
hinge region is not conserved [79]. All HPVs possess the ability to produce an 
additional E2 isoform, designated E8^E2. E8^E2 retains both the hinge and DBD 
of full-length E2 but lacks the N-terminal TAD. Instead, E8^E2 is produced from a 
spliced transcript that links the sequence of an alternative reading frame within 
E1 to the E2 hinge. This results in a short (10-13 residue) N-terminal peptide (E8) 
being linked to the E2 hinge in place of the TAD. PV E2 proteins exist as highly 
stable homodimers (E2/E2, E8^E2/E8^E2) or heterodimers (E2/E8^E2) that are 
formed through the E2 DBD [86, 92-94] and following dimerization no further 
mixing of E2 monomers occurs [86]. E2/E8^E2 heterodimers are capable of 
   20 
initiating viral DNA replication, as well as regulating gene transcription but unlike 
full-length E2 homodimers are defective in genome partitioning [79, 95-97].  
 
E2 is essential for effectual initiation of viral replication [79] and is the main 
determinant for specificity during recruitment of replicative factors to the HPV 
LCR [98]. E2-mediated recruitment involves protein-protein interactions and the 
binding of E2 with specific DNA consensus motifs (ACCGN4CGGT, ACCN6GGT) 
located within the LCR [99-101]. As previously discussed, E2 initiates viral 
replication primarily by recruiting E1 to the viral ori [67, 102]. E2 recruitment of E1 
to the ori enables efficient initiation of viral genome replication, as the poor 
sequence specificity of HPV E1 for E1BS within the viral LCR precludes efficient 
viral replication in the absence of E2. While artificially high levels of E1 can 
initiate viral genome replication in vitro, in vivo replication requires E2 to localize 
E1 to the ori [103]. E2 can also stimulate initiation of replication by displacing 
nucleosomes from the viral ori [104].  
 
E2 is essential to the regulation of viral gene transcription and this is achieved by 
localizing host factors that activate or repress transcription to the viral LCR [79]. 
For example, E2 can stimulate transcription through recruitment of Brd4 [105] 
and SMARCA2 [106] to viral episomes. Alternatively, E2 can regulate viral 
transcription by sterically hindering the association of certain host factors with 
viral DNA, such as TATA-binding protein [107] and SP1 [108].  
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HPV transcription is also regulated by E8^E2-mediated repression [79]. E8^E2 
represses transcription by competing with E2 for E2BS within the viral LCR, 
thereby preventing E2 from recruiting factors that would activate transcription 
[109-111]. Additionally, E8^E2 represses transcription through interactions with 
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Figure 1.6. HPV E2.  (Top) Full-length HPV E2 is comprised of an N-terminal 
transactivation domain (TAD- green) connected by a disordered linker (Hinge- 
blue) region to a C-terminal DNA binding/oligomerization domain (DBD- purple). 
(Bottom left) HPV-16 TAD crystal structure at 1.9 Å (PDB ID: 1DTO, [114], Mol*, 
RCSB PDB). (Bottom right) HPV-31 DBD crystal structure at 2.4 Å (PDB ID: 
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E2-mediated transcriptional regulation is also important in preventing cells from 
progressing towards malignancy. E2 regulates viral oncoprotein expression by 
repressing the early promoter and loss of E2 function results in overexpression of 
E6 and E7 [116-120]. While low levels of E6 and E7 are necessary for 
maintaining viral episomes and stable replication [45], overexpression of E6 and 


















   24 
1.3 HPV Life Cycle 
 
HPV infection occurs when microabrasions compromise the integrity of the 
epithelium, enabling HPV virion access to basal keratinocytes (discussed in 
detail in Chapter 5.1)[122]. Following initial interactions of the HPV capsid with 
the cellular extracellular matrix, the viral L1 major capsid protein is cleaved by the 
KLK8 protease and then binds with the primary HPV receptor, heparin sulfate 
proteoglycans (HSPGs) (Figure 1.7). This binding induces conformational 
changes in the viral capsid that expose the L2 minor capsid protein to furin 
proteolytic cleavage. Cleavage of L2 induces conformational changes in the HPV 
capsid which are believed to increase the affinity of L1 for an unidentified cell 
surface receptor that mediates endocytic entry of HPV into host cells. Upon HPV 
entry into basal keratinocytes the viral capsid uncoats as endosomes mature and 
acidification increases. Furin-cleaved L2 then facilitates retrograde trafficking of 
viral genomes towards the nucleus in a process mediated by the host cell 
retromer complex [123]. Viral genomes reside within trafficking vesicles in the 
perinuclear space until breakdown of the nuclear envelope during mitosis [124-
126]. Following nuclear envelope breakdown HPV DNA enters the cell nucleus 
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Figure 1.7. HPV infection and trafficking. HPV capsids are cleaved in the host 
cell ECM by the KLK8 protease. Capsids then bind heparin sulfate proteoglycans 
(HSPG) on the cell surface followed by cleavage of the L2 capsid protein. 
Internalization of viral nucleocapsids occurs after interactions with a secondary 
cellular receptor. Viral genomes are then trafficked from early to late endosomes 
where capsids will disassemble and L2 will mediate retrograde trafficking of viral 
genomes towards the nucleus. Upon breakdown of the nuclear envelope HPV 
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HPV replication can be divided into 3 hypothetical phases; establishment, 
maintenance, and amplification [130] (Figure 1.8). The phase of the viral 
replicative program is tied to the level of host epithelial cell differentiation, 
transitioning from one to the next as the infected host cell progresses through the 
epithelial layers towards terminal differentiation. However, precisely how the virus 
is stimulated to switch from one phase of replication to the next is unclear.  
 
Upon nuclear entry, HPV establishes low copy numbers (establishment) within 
the nucleus of the infected host cell [130]. The initial establishment phase is 
believed to require E1 and E2 and utilize the previously described mechanism of 
viral replication, whereby E2 initiates duplication of viral genomes through the 
recruitment of E1 to the viral ori [130, 131]. Following establishment the viral 
replicative program switches into the maintenance phase. During maintenance 
viral episomes are duplicated once per cell cycle [132] and are equally 
partitioned to daughter cells following division by E2 [81-84], thereby maintaining 
the established copy number per cell.  As infected host cells become increasingly 
differentiated during the progression towards the outer epithelial layers viral 
replication switches to the amplification phase [133, 134]. This phase of the viral 
replicative program is characterized by the amplification of HPV genomes until 
roughly 1000 copies are obtained per cell and culminates in the packaging of 
genomes into infectious viral particles by L1 and L2 capsid proteins.  
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Amplification phase utilizes the host DNA damage response (DDR) pathway, 
which has been shown to be essential for completion of the viral replicative 
program [135]. HPV infection activates both ATM [136] and ATR [137, 138] DDR 
pathways. The primary DDR pathway believed to be involved in HPV replication 
is the homologous recombination DNA-damage response (HR-DDR) [139] 
(Figure 1.9). HR-DDR is a high fidelity, error-free method by which double-strand 
DNA breaks are repaired using an available homologous DNA template [140]. 
The cellular DDR kinase, ATM, is required for amplification phase replication 
occurring through the HR-DDR [136] and unsurprisingly, several HR-DDR 
proteins are essential for duplicating viral genomes during this phase, such as 
Rad51 [141, 142], SMC1 [143], BRCA1 and NBS1 [144]. However, precisely how 
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Figure 1.8. HPV life cycle. Following an insult to the epithelium HPV 
nucleocapsids infect basal keratinocytes and establish infection mediated by E1 
and E2 proteins (establishment). The viral replicative program then enters 
maintenance phase and viral genome copy numbers are maintained dependent 
upon E1, E2, E6 and E7 proteins. Amplification phase occurs in the outer 
epithelial layers wherein viral genome copy numbers are amplified to thousands 
of copies per cell. HPV genomes are then packaged into infectious virions by L1 
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Figure 1.9. Homologous recombination DNA repair. HR-DDR is an error-free 
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1.4 Structural Maintenance of Chromosomes 5/6 (SMC5/6) Complex 
 
SMC5/6 belongs to the evolutionarily conserved structural maintenance of 
chromosomes protein family, which includes SMC1/3 (cohesin) and SMC2/4 
(condensin) [145]. Similar architectures of all SMC complexes can be found in 
both eukaryotes and prokaryotes, with complexes adopting a closed ring 
structure comprised of two core SMC heterodimers and multiple non-SMC 
subunits. All SMC complexes utilize ATP hydrolysis to facilitate SMC complex 
conformational changes, translocation along chromatin and the driving of 
topological changes in host chromatin [146]. Essential for development and cell 
viability, SMC5/6 is ubiquitously expressed in all tissues. SMC5/6 is localized 
within the nuclei of cells where it performs a variety of cellular functions that 
remain less well defined than its SMC1/3 and SMC2/4 counterparts. The primary 
functions of SMC5/6 are believed to be involved in the DNA damage response, 
where SMC5/6 has been shown to be essential to the functioning of the 
homologous recombination repair pathway used to mediate error-free correction 
of double-strand DNA breaks, as well as in restarting stalled replication forks 
[147]. However, precisely how SMC5/6 function in this pathway, or the full 
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1.4.1 Structure 
 
The SMC5/6 complex is comprised of two SMC subunits SMC5 and SMC6, and 
four non-SMC elements (NSE1-4) which join to form a ring-shaped structure 
used to topologically entrap DNA [147] (Figure 1.10). Both SMC5 and SMC6 
peptides fold back upon a central hinge region that connects to N- and C-terminal 
globular domains via a long coiled-coil alpha helical arm [148]. The N- and C-
terminal globular domains contain Walker A and Walker B motifs respectively 
and provide the ATPase activity that is essential to opening and closing of the 
ring structure, binding DNA and translocation along chromatin. SMC5 and SMC6 
then form heterodimers via their central hinge domains [148, 149]. The 
characteristic ring structure of the SMC5/6 complex is formed following the 
binding of the C-terminus of the NSE4 kleisin subunit with the distal portion of the 
SMC5 head domain and the base of the coiled-coil of SMC6 via its N-terminus 
[150]. In addition to closing the ring structure, NSE4 mediates the transient 
contact of SMC5/6 head domains to facilitate ATP hydrolysis. NSE1 and NSE3 
bind NSE4 [148], forming the NSE1/3/4 sub-complex that enables NSE3-
dependent DNA binding activity of SMC5/6 and mutations of key basic residues 
within the C-terminal DNA binding domain of NSE3 render SMC5/6 unable to 
bind DNA [151] (Figure 1.11). Intriguingly, while the NSE1 subunit of this sub-
complex possesses a RING-like finger motif associated with E3 ubiquitin ligase 
activity, its function is not believed to be ubiquitination of substrates, but rather 
the assembly of the NSE1/3/4 trimer, as well as SMC5/6 stability and recruitment 
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to chromatin in response to DNA damage [152]. Amongst SMC protein family 
members, SMC5/6 is unique in possessing intrinsic enzymatic activity via an 
NSE2 SP-RING SUMO ligase subunit that is bound to the coiled-coil arm of 
SMC5 [153, 154]. While the full complement of NSE2 substrates have yet to be 
identified, NSE2, SMC5, SMC6, NSE3 and NSE4 have all been shown to be 
substrates for NSE2-mediated SUMOylation [155-158]. With the exception of 
NSE2, depletion of any one subunit results in SMC5/6 complex formation failure 
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Figure 1.10. SMC5/6. Structural diagram of the Homo sapiens SMC5/6 complex. 
SMC5 and SMC6 form heterodimers via the subunits central hinge region and 
the complex ring is closed by kleisin subunit, NSE4. NSE1 and NSE3 bind NSE4 
to form the NSE1/3/4 sub-complex. The NSE2 SUMO ligase is attached to the 
coiled-coil arm of SMC5. 
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Figure 1.11. NSE1/3 sub-complex. (Left) Molecular surface representation of 
the NSE1/3 sub-complex (PDB ID: 3NW0) with key DNA binding basic residues 
highlighted in green. (Right) Postulated DNA binding pose of the NSE1/3 sub-
complex with representative B-form DNA and phosphate contacting basic 
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1.4.2 Recruitment and Localization 
 
SMC5/6 associates with DNA during S phase of the cell cycle [159-161], but the 
majority of SMC5/6 is not present on DNA during mitosis [146]. Precisely how 
human SMC5/6 is localized to DNA and the factors involved in mediating this 
process remain to be fully understood. During the HR-DDR, SMC5/6 localization 
factor 1 and 2 (SLF1/2) have been proposed to recruit SMC5/6 to host chromatin 
during DNA damage in a Rad18-dependent manner [162]. In this model the 
coiled-coil arm of SMC6 is bound by the SLF2 subunit of the SLF1/2 
heterodimer. RNF8-mediated mono-ubiquitination of γH2AX stimulates ubiquitin 
chain-elongation via RNF168 polyubiquitination. This is followed by SMC5/6 
recruitment to sites of DNA damage by Rad18 binding γH2AX ubiquitin chains 
and SLF1. However, recent findings suggest that SMC5/6 localization to viral 
DNA and plasmids may differ than those facilitating its recruitment to damaged 
host DNA, and instead be mediated through an alternative pathway. SMC5/6 has 
been shown to bind episomal HBV covalently closed circular DNA (cccDNA) and 
HSV-1 DNA, but not be associated with integrated viral DNA [163, 164]. This 
preferential association with episomal viral DNA is postulated to involve the 
cellular E3 ligase, PJA1 [164]. In this model PJA1 replaces NSE1 in the 
NSE1/3/4 trimeric subcomplex and directs the SMC5/6 complex to episomal viral 
DNA, but how this occurs remains unclear. 
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1.4.3 Functions 
 
Despite structural similarities to SMC1/3 and SMC2/4, the functions of SMC5/6 
remain enigmatic [147]. SMC5/6 associates with host chromatin to rescue stalled 
replication forks [165], topologically entrap extrachromosomal DNA and mediate 
homologous recombination DNA repair (HR-DDR) [166], but precisely how 
SMC5/6-mediates these functions remains unclear [147]. The role of SMC5/6 in 
HR-DDR requires the complexes NSE2 SUMOylation activity, as loss of NSE2 
renders cells hypersensitive to DNA damage [155, 167]. However, little is known 
about what substrates of NSE2 are required for this function [155].  
 
Recently, antiviral roles have been described for SMC5/6 whereby SMC5/6 
restricts viral DNA transcription of hepatitis B [163, 164, 168, 169] and herpes 
simplex-1 (HSV-1) viruses [164], but how SMC5/6 represses transcription of 
extrachromosomal DNA templates has yet to be determined. SMC5/6 reportedly 
interacts with both high, and low-risk HPV E2 proteins [170-172] and is 
purportedly involved in HPV genome maintenance [173], but the full extent of 
SMC5/6 functions during the life cycle of HR-HPV remain to be fully understood. 
 
I examined interactions of SMC5/6 complex subunits SMC6 and NSE3 with  
HPV-31 E2 and E1 proteins, as well as their roles during the maintenance phase 
of the HPV-31 replicative program. Previously reported antiviral functions of 
SMC5/6 during HBV and HSV-1 infections led me to hypothesize that SMC5/6 
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would function as a repressor of the HPV-31 life cycle. I found that depletion of 
SMC6 and NSE3 resulted in increased HPV-31 replication and transcription, 
suggesting that the SMC5/6 complex represses the replicative program of HPV-
31. My data demonstrate that SMC6 is present on episomal HPV-31 genomes 
and associates with E2 proteins but not E1/E2 replicative complexes. I find that 
SMC6 interactions with E2 are reduced in the presence of E1, implying that 
SMC6 competes with E1 for E2 binding. Taken together, these results indicate 
that SMC5/6 functions as a repressor of the HPV-31 replicative program 
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CHAPTER 2 
MATERIALS & METHODS 
 
2.1 Plasmids, siRNA and Antibodies 
 
Plasmids used were FLAG-SMC6/pcDNA3 (GenScript), HPV-31 FLAG-
E2/pcDNA3, HPV-31 FLAG-E2mt (residues 205-372; [174]), HPV-31 V5-
E2/pcDNA3, HPV-31 HA-E1/pcDNA3, and pcDNA3 (Table A.3). siRNA depletion 
of SMC5/6 subunits used esiGFP (Sigma-Aldrich; EHUEGFP), esiSMC6 (Sigma-
Aldrich; EHU026931), siScramble DsiRNA (IDT; 51-01-19-08), siSMC6 (IDT; 
hs.Ri.SMC6.13.2 ) and siNSE3 (IDT; hs.Ri.NDNL2.13.1) (Table A.4). shRNA 
knockdowns used lentiviral transduction of either shGFP/pLKO.1 (Sigma-Aldrich; 
SHC002) or NSE3/pLKO.1 (Sigma-Aldrich; TRCN0000115778) constructs 
packaged in HEK293TT cells by co-transfection with PAX2 and MD2.G lentiviral 
packaging vectors. Antibodies included mouse M2 anti-FLAG (Sigma), mouse 
anti-V5 (Invitrogen), rabbit anti-V5 (Cell Signal Technologies), rabbit anti-NSE3 
(Abcam), mouse anti-SMC6 (Abgent), rabbit anti-SMC6 (Bethyl), rat anti-HPV-31 
E1 [175], mouse DM1a anti-α-tubulin (Sigma), mouse anti-β-actin (Sigma), 
mouse TVG-261 anti-HPV-16 E2 (Abcam), sheep anti-HPV-16 E2 [176], and 
control rabbit IgG (Jackson). Chromatin immunoprecipitation (ChIP) experiments 
used rabbit anti-HPV-31 E2 (10008, final bleed; [175]), rabbit anti-SMC6 (Bethyl), 
rat anti-HPV-31 E1 [175] and rabbit IgG (Jackson) antibodies. A complete list of 
antibodies can be found in Tables A.5. 
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2.2 Cell Culture 
 
HEK293 and HEK293TT cells (J. Schiller and C. Buck) were maintained in 
Dulbecco’s Modified Eagle Medium (Life-Technologies) supplemented with 10% 
fetal bovine serum (Atlas Biologicals) and 5% penicillin/streptomycin (Life-
Technologies) at 37oC and 5% CO2. CIN612-9E cells (L. Laimins) maintaining 
episomal HPV-31 genomes, were cultured in E-media with mitomycin C treated 
J2 3T3 fibroblast feeders (H. Green). CIN612-9E/shGFP and CIN612-
9E/shNSE3 were cultured as parental CIN612-9E cells, but with 1μg/mL 
puromycin. CIN612-9Ei (L. Laimins) are derived from CIN612-9E cells, but 
possess integrated, not episomal, HPV-31 genomes and were maintained in E-
media. N/TERT foreskin keratinocytes (N/TERT; I. Morgan), a cell line 
immortalized by hTERT expression, were cultured in Keratinocyte-SFM (Life-
Technologies) supplemented with human recombinant EGF and bovine pituitary 
extract, as well as hygromycin B (4μg/mL) at 37oC and 5% CO2.  N/TERT/HPV-
16 E2 were cultured as parental N/TERT cells. HaCaT/pcDNA3 and 
HaCaT/HPV-31 FLAG-E2 in Dulbecco’s Modified Eagle Medium (Life-
Technologies) supplemented with 10% fetal bovine serum (Atlas Biologicals) and 
5% penicillin/streptomycin (Life-Technologies) with 200μg/mL G418 at 37oC and 
5% CO2. NIKS/HPV-31, a cell line maintaining episomal HPV-31, were cultured 
in F-media with 250μg/mL G418 and mitomycin C treated J2 3T3 fibroblast 
feeders. A complete list of cell lines used in these studies can be found in  
Table A.2. 
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E-media (Filter sterilize and store at 4oC) 
• 750 mL  DMEM       
• 250 mL  F-media (Ham’s)     
• 50 mL  100% FBS      
• 24.3 mg  adenine 
• 1 mL   5 mg/mL insulin     
• 1 mL   20 μg/mL EGF      
• 2.5 μL  cholera toxin      
• 10 mL  100X Penicillin/Streptomycin (Cf = 1X)   
• 100 μL  5 mg/mL hydrocortisone    
• 1 mL  5 mg/mL transferrin   
F-media (filter sterilize and store at 4oC) 
• 750 mL  F-media (Ham’s) 
• 250 mL  DMEM 
• 50 mL  100% FBS 
• 24.3 mg  adenine 
• 1 mL   5 mg/mL insulin 
• 2 mL   10 μg/mL EGF 
• 2.5 μL  cholera toxin 
• 10 mL  100X Penicillin/Streptomycin (Cf = 1X) 
• 100 μL  5 mg/mL hydrocortisone 
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2.3 Co-immunoprecipitation and Immunoblotting 
 
HEK293 and HEK293TT cells were transfected using polyethylenimine (PEI; 
2mg/mL) (Sigma) per the manufacturer’s protocol. Cells were seeded onto 10cm 
plates and transfected, then after 48hrs cells were lysed in 0.5% NP-40/150mM 
NaCl/50mM Tris-HCl (pH 8)/10% glycerol and protease inhibitor cocktail (Sigma). 
Samples were then rotated for 1hr at 4oC after the addition of 4μL benzonase 
(Millipore), then spun for 10min at 4oC and supernatant collected. FLAG 
immunoprecipitation experiments had samples rotated at 4oC with 20μL of 50% 
M2 agarose bead slurry (Sigma). SMC6 immunoprecipitation experiments used 
rabbit anti-SMC6 antibody. Beads were then washed 4 times, alternating 0.5% 
NP-40/0.5M NaCl/50mM Tris-HCl (pH 8)/10% glycerol and 0.5% NP-40/150mM 
NaCl/50mM Tris-HCl (pH 8)/10% glycerol washes, then boiled for 3-5min at 
95oC. Samples were subjected to SDS-PAGE and subsequent Western blot 
analysis using a 4-12% Bis-Tris gradient gel (GenScript), then transferred onto 
PVDF membranes (Millipore) using semi-dry transfer. PVDF membranes were 
blocked in 5% milk/1X PBS/Tween-20 (0.1%), then probed rocking overnight at 
4oC with primary antibodies. Next, antibody detection was performed using 
appropriate secondary antibodies with chemiluminescence substrates (GE) and 
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2.4 Protein Isolation 
 
To analyze the influence of HPV E2 on SMC6 stability total protein was isolated 
from cells stably expressing either HPV-31 (HaCaT) or HPV-16 (N/TERT). Cells 
were lysed in 10% SDS/150 mM NaCl lysis buffer lysis buffer and protease 
inhibitor cocktail, then Laemmli buffer added and samples boiled. SDS-PAGE 
was performed using a 4-12% Bis-Tris gradient gel (GenScript) and Western blot 
analysis performed as described for co-immunoprecipitation experiments. 
Densitometry was performed using ImageStudios software and SMC6 protein 
expression normalized relative to loading controls. Statistical significance was 
determined using a two-tailed Student’s T-test. To confirm depletion of SMC6 
and NSE3 in RNAi knockdown experiments, total protein was isolation and 
Western blot analysis was performed as described above.  
 
10% SDS/150 mM NaCl lysis buffer [177]: 
• 333 μL Tris pH 8.0 (Cf = 10 mM) 
• 1.5 mL 5 M NaCl (Cf = 150 mM) 
• 10 mL  10 % SDS (Cf = 2 %)  





   43 
2.5 qPCR DNA Replication Assay 
 
Transient depletion of SMC5/6 subunits was performed in CIN612-9E and 
NIKS/HPV-31 cells reverse-transfected with 15nM or 20nM siRNA, respectively, 
using Lipofectamine 2000 (Life-Technologies) per the manufacturer’s protocol. 
The following day media was changed and cells returned to incubate for an 
additional 24 hours. DNA isolation was performed by phenol/chloroform 
extraction as previously described [178]. Purification of DNA was performed by 
ethanol precipitation. Briefly, DNA samples were mixed with 100% ethanol and 
3M sodium acetate at a ratio of 1:2:0.01, then incubated at -20oC for 1 hour (or 
overnight) to precipitate DNA. Samples were then spun at 4oC for 1 hour to pellet 
DNA, then supernatant removed and residual ethanol allowed to evaporate at 
room temperature. DNA pellets were then resuspended in either MQ-H2O or TE. 
qPCR was performed as described above with Ct values normalized to β-actin 
and fold-change calculated relative to control groups. All experiments were 
performed in triplicate and statistical significance determined by either two-tailed 
(CIN612-9E), or one-tailed (NIKS/HPV-31) Student’s T-test. 
qPCR cycling conditions 
• Initial Denaturation:  95oC x3 min 
• Denaturation:  95oC x10 sec 
• Annealing/Elongation: 60oC x30 sec 
• Melt Curve:   60-95oC, 0.5oC increments 
• Cycles:   40 
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2.6 RT-qPCR 
 
RNA was isolated using TRIzol reagent and PureLink RNA Micro kits (Invitrogen) 
per the manufacturer’s protocol. RQ1 DNase (Promega) was used per the 
manufacturer’s protocol to remove any possible genomic DNA contaminants. 
Reverse transcription was performed using SuperScript III reverse transcriptase 
(Invitrogen) per the manufacturer’s protocol, then qPCR performed as described 
above with Ct values normalized to GAPDH, or β-actin, fold-change calculated 
relative to control groups and primers listed in Table A.6. All experiments were 
performed in triplicate and statistical significance determined by either two-tailed 
(CIN612-9E), or one-tailed (NIKS/HPV-31) Student’s T-test. 
 
RT-PCR cycling conditions 
• Cycle 1  25oC x10 min 
• Cycle 2  50oC x50 min 
• Cycle 3  70oC x15 min 
• Cycle 4  12oC x ∞ 
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2.7 Site-directed Mutagenesis 
 
Replication defective HPV-16 genomes were generated by site-directed 
mutagenesis (SDM) for future studies examining the role of SMC5/6 as a 
transcriptional repressor of HPV. Briefly, a translation termination linker (TTL) 
encoding 3 sequential stop codons was used to mutate the viral E1 open reading 
frame using PCR. The site selected for placement of the E1 TTL would mutate 
nucleotides encoding E1 amino acids 149-151 and remove a KasI restriction 
endonuclease site within E1 ORF of HPV-16/pMC (Figure 2.1), but not disrupt 
E1^E4 or E8^E2 (Figure 2.2). Removal of the KasI site was used for screening of 
candidate bacterial colonies using restriction digest and agarose gel 
electrophoresis. SDM PCR reactions were set up using HPV-16/pMC as follows: 
 
SDM Reaction: 
• 100 ng HPV-16/pMC 
• 10.0 μL 5X Phusion Buffer 
• 1.0 μL  10 μM dNTP 
• 1.0 μL  E1 TTL primer  
• 1.0 μL  Phusion polymerase 
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PCR cycling conditions 
• Initial Denaturation:  98o C x1 min 
• Denaturation:  98o C x15 sec 
• Annealing   60o C x15 sec 
• Elongation:   72o C x8-12 min 
• Repeat to 2:   20 cycles 
• Final Elongation:  72o C x5 min 
• Final:    12o C x ∞ 
 
PCR products were digested with 1 μL DpnI (NEB) at 37oC to remove unmodified 
template DNA, then DpnI heated inactivated at 80oC for 20 minutes. Bacteria 
were then transformed, selected, and plasmid DNA isolated using Pureyield 
Plasmid Miniprep (Promega) per the manufacturer’s specifications. DNA was 
then digested with KasI and run on agarose gels to screen for potential colonies 
containing the desired mutation. Candidate colonies were then sequenced to 
confirm genomes possessed the desired mutations within E1. 
 
HPV-16 E1TTL Primer (F): 5’-atgttacaggtagaaTGATAATGAgagactgaaacacca-3’ 
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Figure 2.1. HPV-16/pMC. HPV-16 genomes in the pMC backbone were selected 
for use in inserting a translation termination linker (TTL) into the E1 ORF using 
site-directed mutagenesis. Successful insertion of the TTL into E1 would remove 
the KasI site within the E1 ORF and enable restriction digest screening of 




KasI             
KasI             
KasI             
HPV-16/pMC
(11988 bp)
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Figure 2.2. HPV-16 E1 mutant site-directed mutagenesis. (Top) Wild-type 
HPV-16 E1 possesses an N-terminal regulatory region (NRR), DNA-binding 
domain (DBD), oligomerization domain (O), helicase domain (Helicase) and C-
terminal brace (B). E1^E4 and E8^E2 proteins are produced from spliced 
transcripts that include short peptides within the E1 ORF. (Bottom) HPV-16 
genomes would have a translation termination linker (TTL – 3 sequential stop 
codons; UGA, UAA, UGA) placed within the viral E1 ORF after the codon for 
amino acid 148 and mutate G149, R150 and H151 to stop codons. E1 TTL 
insertion was downstream of E1^E4 (E1 nt: 1-16) and E8^E2 (E1 nt: 401-438) 



















   49 
2.8 Chromatin Immunoprecipitation 
 
ChIP (Figure 2.3) was performed using CIN612-9E cells and ChIP-IT Express 
Enzymatic kit (Active Motif) according to the manufacturer’s protocols. qPCR was 
performed using SsoFast Evagreen Mastermix (Bio-Rad) with primers specific to 
sequences within the HPV-31 L1 region, E2BS in the 5’ region of the LCR, and 
E2BS located adjacent to the viral ori and early promoter (Figure 2.4). Primer 
sequences are listed in Table A.6. Data were analyzed using BioRad CFX with Ct 
values normalized to input samples and fold change calculated relative to control 
IgG samples (set to 1). Statistical significance was determined by comparison of 
fold change values against negative DNA binding sequences or control IgG using 
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Figure 2.3. Chromatin immunoprecipitation. Diagram of chromatin 
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Figure 2.4. HPV-31 ChIP sites. CIN612-9E cells were tested for the presence of 
E2 and SMC6 on the viral LCR and flanking L1 region. Primers to the viral L1 
region generated an amplicon roughly 464bp from the 5’ upstream E2 binding 
site (E2BS - red) of the LCR. The 5’ E2BS amplicon was approximately 580bp 
upstream of the 3’ E2BS that was located adjacent to the viral ori (yellow) and 
early promoter (blue). Primer annealing sites are indicated by black arrows (right 

























3.1 SMC6 and NSE3 Interactions with HPV-31/-16 E2 
 
The SMC5/6 complex (Figure 3.1A) subunit SMC6 reportedly co-precipitates with 
several HPV E2 proteins (Figure 3.1B) [170-172] so I began this investigation by 
attempting to validate this interaction with HPV-31. HEK293 cells were 
transfected with either FLAG-SMC6, HPV-31 V5-E2, or both plasmids, then 
FLAG-SMC6 immunoprecipitation performed using M2 anti-FLAG antibody. Both 
HPV-31 V5-E2 and NSE3 (positive control) co-immunoprecipitated (co-IP) with 
SMC6 (Figure 3.1C). In the reciprocal experiment, antibody to the V5 epitope 
pulled-down FLAG-SMC6 but not the SMC5/6 subunit NSE3 (Figure 3.1D). Next, 
I sought to confirm an interaction of SMC6 with HPV-16 E2. HEK293TT cells 
were transfected with FLAG-SMC6, HPV-16 FLAG-E2, or both plasmids and 
then IP performed using anti-SMC6 antibody. I observed SMC6 co-IP NSE3 and 
HPV-16 FLAG-E2 when co-expressed with FLAG-SMC6 (Figure 3.2). These data 
support that SMC6 interacts with both HPV-31 and HPV-16 E2 proteins. This 
shows that NSE3 does not associate with HPV-31 E2, suggesting that E2 may 
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Figure 3.1. SMC6 co-immunoprecipitates HPV-31 E2. (A) Figure 
representation of the SMC5/6 complex with subunits investigated in red. (B) 
Figure representation of HPV-31 full-length E2. (C) V5-tagged HPV-31 E2 and 
FLAG-SMC6 were transfected (+) into HEK293 cells. Forty-eight hours later 
FLAG was immunoprecipitated and immunoblotting performed using rabbit anti-
V5, mouse M2 anti-FLAG and rabbit anti-NSE3 antibodies. (D) As in C,but using 
HEK293TT cells and IP using rabbit anti-V5 antibody. Immunoblotting was 
performed using rabbit anti-V5, mouse M2 anti-FLAG, rabbit anti-SMC6 and 
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Figure 3.2. FLAG-SMC6 co-immunoprecipitates HPV-16 E2. FLAG-tagged  
HPV-16 E2 and FLAG-SMC6 were transfected into HEK293TT cells. Forty-eight 
hours later immunoprecipitation was performed using either rabbit IgG or rabbit 
anti-SMC6 antibodies, then immunoblotting performed using mouse M2 anti-
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Structurally, HPV E2 is comprised of an N-terminal transactivation domain (TAD) 
connected to a C-terminal DNA binding/dimerization domain (DBD) by a poorly 
conserved linker region. To identify the region of E2 required for these 
interactions, HEK293TT cells were transfected with FLAG-SMC6, FLAG-tagged 
full-length E2, or FLAG-tagged truncated E2 expressing the E2 hinge and DBD 
(Figure 3.3A). Co-IP was performed using anti-SMC6 antibody and showed full-
length HPV-31 FLAG-E2 and NSE3 co-IP with SMC6, but not truncated E2 
(Figure 3.3B). These data demonstrate that SMC6 association with HPV-31 E2 
requires the E2 transactivation domain, inferring E2 interacts with the full-length 
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Figure 3.3. SMC6 co-immunoprecipitates with full-length HPV-31 E2. 
(A) Figure representation of FLAG-tagged E2 proteins used to identify region of 
SMC6 interaction. (B)  FLAG-SMC6, full-length FLAG-tagged HPV-31 E2 and 
FLAG-tagged HPV-31 truncated E2 mutant were transfected into HEK293TT 
cells. Forty-eight hours later immunoprecipitation was performed using either 
rabbit IgG or rabbit anti-SMC6 antibodies, then immunoblotting performed using 
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3.2 SMC5/6 Complex and HPV-31 Replication/Transcription 
 
SMC5/6 purportedly inhibits the life-cycle of DNA viruses by restricting viral 
transcription in studies of both hepatitis B [163, 164, 180, 181] and herpes 
simplex-1 viruses [164]. I questioned if the previously described antiviral 
functions of SMC6 and its interactions with HPV E2 indicated that SMC5/6 
functions as a repressor of HPV-31 replication or transcription. I began 
investigating this by depleting CIN612-9E cells of SMC6 using siRNA 
knockdown, then examining HPV-31 DNA content and transcript abundance. 
CIN612-9E cells transfected with siRNA targeting SMC6 had reduced SMC6 
protein (Figure 3.4A) and transcript levels (Figure 3.4B) compared to those 
transfected with control siRNA. Indeed, SMC6 depletion resulted in increased 
viral DNA content relative to the control group (Figure 3.4C). Similarly, RT-qPCR 
analysis revealed that SMC6 depletion resulted in increased HPV-31 E2 and E1 
transcript abundance (Figure 3.4B). I sought to further validate these findings by 
examining the effects of depleting both SMC6 and SMC5/6 subunit, NSE3 in 
CIN612-9E cells by siRNA knockdown (Figure 3.5A). SMC6 and NSE3 depleted 
cells displayed increased HPV-31 DNA content (Figure 3.5B) and viral E8^E2 
transcript abundance (Figure 3.5C). To confirm these findings, I performed an 
analogous experiment in episomal maintaining NIKS/HPV-31 keratinocytes. 
Similar results were found in that depletion of either SMC6 or NSE3 resulted in 
increased HPV-31 DNA content, but only NSE3 knockdown increased E8^E2 
viral transcripts relative to controls in NIKS/HPV-31 (Figure 3.5D-F). To 
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determine if stable NSE3 depletion increased HPV-31 DNA content, CIN612-9E 
cells were transduced with lentivirus containing constructs with either non-
targeting shRNA, or shRNA targeting NSE3 (Figure 3.6A). Unexpectedly, stable 
depletion of NSE3 did not influence viral replication relative to controls when 
HPV-31 DNA content was analyzed by qPCR (Figure 3.6B). Taken together, 
these data show that transient depletion of SMC6 and NSE3 subunits in CIN612-
9E and NIKS/HPV-31 results in increased HPV-31 replication and transcription 
(Table 3.1), implying that SMC6 and NSE3 are repressors of the HPV-31 















   59 
 
Figure 3.4. SMC6 inhibits HPV-31 replication and transcription. (A) Forty-
eight hour siRNA knockdown of SMC6 resulted in decreased SMC6 expression 
in CIN612-9E cells. (B) Transient depletion of SMC6 increased HPV-31 DNA 
content in CIN612-9E cells following 48hr siRNA knockdown. Ct values were 
normalized to B-actin and fold change shown relative to control group (set to 1; 
n=3). (C) As in B, with RNA transcript abundance Ct values normalized to 
GAPDH and fold change shown relative to control group (set to 1; n=3). Western 
blot analysis was performed once to confirm knockdown, DNA and RNA 
experiments were performed in triplicate. Two-tailed Student’s T-test was used to 
determine statistical significance where * = p<0.05, ** = p<0.005, *** = p<0.0005 
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Figure 3.5. SMC6 and NSE3 repress HPV-31 replication and transcription  
in CIN612-9E and NIKS/HPV-31 cells. (A) Forty-eight hour siRNA knockdown of 
SMC6 and NSE3 resulted in decreased target protein abundance in CIN612-9E 
cells. (B) Transient depletion of SMC6 increased HPV-31 DNA content in 
CIN612-9E cells following 48hr siRNA knockdown. Ct values were normalized to 
β-actin and fold change shown relative to control group (set to 1; n=3). (C) As in 
B, but RNA transcript abundance Ct values normalized to β-actin and fold change 
shown relative to control group (set to 1; n=3). (D) As in A, with NIKS/HPV-31 
cells. (E) As in B, with NIKS/HPV-31 cells. (F) As in C, with NIKS/HPV-31 cells. 
All experiments were performed in triplicate and statistical significance 
determined by two-tailed (CIN612-9E) or one-tailed (NIKS/HPV-31) Student’s T-
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Table 3.1. SMC6 and NSE3 siRNA knockdown summary. Increased 
replication or transcription indicated by ‘ ⇧ ’ and no change indicated by ‘-/- ‘. 
 
Cell Line siRNA Replication Transcription 
CIN612 siNSE3 ⇧ ⇧ 
siSMC6 ⇧ ⇧ 
NIKS/31 siNSE3 ⇧ ⇧ 
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Figure 3.6. Stable NSE3 depletion does not influence HPV-31 replication in 
CIN612-9E cells. (A) shRNA knockdown of NSE3 resulted in decreased target 
protein abundance in CIN612-9E cells. (B) NSE3 depletion did not influence 
HPV-31 DNA content in CIN612-9E cells. Ct values were normalized to β-actin 
and fold change shown relative to control group (set to 1; n=3). All experiments 
were performed in triplicate and statistical significance determined by two-tailed 
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3.3 SMC6 Associates with HPV-31 Episomes  
 
SMC6 associates with nuclear episomal hepatitis B virus (HBV) cccDNA [163, 
164] and HSV-1 DNA [164], but how SMC5/6 is localized to viral DNA remains 
unclear. SMC6 association with HPV genomes has not been investigated. Similar 
to HBV cccDNA and HSV-1, HPV genomes are maintained as episomes 
adjacent PML nuclear bodies [182], known sites of SMC5/6 localization [181]. 
The association of SMC6 with viral DNA and its interaction with HPV E2 led us to 
question whether SMC6 is present on episomal HPV-31 genomes. To answer 
this, I first validated my ability to immunoprecipitate SMC6 in episomal HPV-31 
maintaining CIN612-9E cells to determine suitability of the cell line for 
subsequent chromatin immunoprecipitation (ChIP) experiments. Total protein 
was isolated from CIN612-9E cells and SMC6 IP performed, followed by 
immunoblotting using anti-SMC6 antibody. SMC6 was detectable in input 
samples and IP samples where anti-SMC6 antibody was used, but not negative 
control rabbit IgG (Figure 3.7A). Next, double-thymidine treatment was used to 
synchronize the cell cycle of CIN612-9E cells in S phase and ChIP performed 
using either HPV-31 E2, SMC6 or rabbit IgG antibodies. qPCR determined that 
HPV-31 E2 was found E2BS within the HPV-31 LCR but not viral L1 region 
(Figure 3.7C). I found SMC6 was not localized to the L1 region but was present 
at the E2BS located within the 5’ end of the LCR and E2BS proximal to the viral 
ori and promoter (Figure 3.7D). E2 has been shown to be present on host DNA 
[81, 183, 184] and its consensus sequences are found throughout the host 
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genome [183]. I examined whether SMC6 and E2 were present at a known host 
replication origin (GM-CSF) as a comparator for association with viral DNA. HPV-
31 E2 but not SMC6 was present at the eukaryotic GM-CSF origin of replication 
(Figure 3.7B). These data show that SMC6 is present on HPV-31 episomes at E2 
binding sites located within the LCR at the 5’ region and near the viral ori and 
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Figure 3.7. SMC6 is present on HPV-31 episomes in CIN612-9E cells.  
(A) Total protein was isolated from CIN612-9E cells and immunoprecipitation 
performed overnight using either rabbit anti-SMC6 or control rabbit IgG 
antibodies, then immunoblotting performed using rabbit anti-SMC6 antibody. (B) 
CIN612-9E cells were synchronized in G1/S phase by double-thymidine block 
and ChIP performed using rabbit anti-HPV-31 E2, rabbit anti-SMC6 or control 
rabbit IgG antibodies. qPCR was conducted using primers to the eukaryotic GM-
CSF origin of replication with primers listed in Table A.6. (C) As in B, but 
examining E2 presence at viral L1, 5’ upstream LCR E2 binding site, and E2BS 
proximal to the viral ori or early promoter (pE) sequences of the HPV-31 genome 
with approximate viral genome location and corresponding primers shown below 
their respective sites on the horizontal axis. (D). As in C, but with SMC6. Ct 
values were normalized to input with control IgG set to 1 and values expressed 
as mean fold change over IgG +/- SEM. ChIP was performed at least 4 
independent times for all locations examined and statistical significance 
determined by one-tailed Student’s T-test as compared to control IgG with           
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3.4 SMC6/NSE3 Interactions with HPV-31 E1 and E1/E2 Complexes 
 
HPV replication depends on E2-mediated recruitment of the viral E1 DNA 
helicase to the viral origin of replication, for which a transient E1/E2-DNA ternary 
complex is formed [46]. The association of SMC6 with E2 and HPV-31 genomes, 
as well as its repression of viral replication, led us to speculate that SMC6 may 
interact with HPV-31 E1/E2 replicative complexes. To explore this, HEK293TT 
cells were transfected with FLAG-SMC6, HPV-31 V5-E2, HPV-31 HA-E1 
plasmids alone or in combination and co-IP reactions performed using anti-SMC6 
antibody. I observed HPV-31 V5-E2 and NSE3 co-IP with SMC6 (Figure 3.8A), 
not HPV-31 HA-E1 when E1 was expressed alone, co-expressed with E2, or 
when FLAG-SMC6 was expressed with E1 and E2 co-expression. Co-expression 
of E1 with FLAG-SMC6 and E2 did not affect SMC6 co-IP of NSE3 but reduced 
the amount of E2 pulled-down by SMC6. To confirm that SMC6 does not co-IP 
HPV-31 E1/E2 complexes or E1 alone, I performed an analogous experiment 
using anti-HPV-31 E1 antibody for co-IP. IP of HPV-31 HA-E1 pulled-down HPV-
31 V5-E2 but not SMC6 or NSE3 (Figure 3.8B). E1 co-IP of E2 was not 
influenced by overexpression of FLAG-SMC6. Together these data demonstrate 
that neither SMC6 nor NSE3 associate with HPV-31 E1 or E1/2 complexes. 
Additionally, data show that expression of E1 during SMC6 IP does not affect 
SMC6 co-IP of NSE3 but inhibits SMC6 pull-down of E2, indicating the E1 
competes with SMC6 for binding of E2.  
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Figure 3.8. SMC6 and NSE3 do not co-immunoprecipitate with HPV-31 
E2/E1 complexes or HPV-31 HA-E1 in HEK293TT cells. (A) FLAG-SMC6, 
HPV-31 V5-E2 and HPV-31 HA-E1 were transfected into HEK293TT cells. Forty-
eight hours later immunoprecipitation was performed using either rabbit IgG or 
rabbit anti-SMC6 antibodies, then immunoblotting performed using anti-SMC6, 
rabbit anti-NSE3, mouse M2 anti-FLAG, or rat anti-HPV-31 E1 antibodies. (B) 
FLAG-SMC6, HPV-31 V5-E2 and HPV-31 HA-E1 were transfected (+) into 
HEK293TT cells. Forty-eight hours later immunoprecipitation was performed 
using rat anti-HPV-31 E1, then immunoblotting performed using rabbit anti-
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3.5 HPV-31/-16 E2 Effects on SMC6 Protein Levels  
 
HPV E2 proteins influence host factor stability and may modify the transcriptional activity 
of host genes [79, 185]. Having validated E2/SMC6 interactions led us to question if E2 
influenced SMC6 abundance. To explore this, I generated HaCaT cells stably 
expressing HPV-31 FLAG-E2 or control vector by G418 selection (Figure 3.9A). No 
changes in SMC6 protein levels in response to HPV-31 E2 expression were observed. 
To confirm this in another cell model I examined SMC6 protein expression in parental 
N/TERT cells and N/TERT/E2 cells stably expressing the HPV-16 E2 protein (Figure 
3.9B). Similarly, no effect on SMC6 stability was found in N/TERT cells with HPV-16 E2 
as compared to control cells. These data indicate that HPV-31 and HPV-16 E2 proteins 
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Figure 3.9. HPV-31/-16 E2 do not affect SMC6 levels. (A) Total protein was 
isolated from control and HPV-31 FLAG-E2 expressing HaCaT cells, then 
immunoblotting performed using mouse M2 anti-FLAG, rabbit anti-SMC6, and 
mouse DM1A anti-α-tubulin antibodies. (B) As in A, but with parental N/TERT 
and N/TERT cells expressing HPV-16 E2 and immunoblotting with mouse TVG-
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3.6 Episomal versus Integrated HPV-31 Effects on SMC6 Protein Levels 
 
HPV E2 regulates the transcription of viral oncoproteins and loss of E2 function 
following genome derepresses HPV E6 and E7 expression [116-118]. While I 
observed no difference in SMC6 stability in response to HPV-31/-16 E2 
expression alone, I questioned whether integration and subsequent derepression 
of viral genome transcription may alter SMC6 levels in the context of viral 
infection. I isolated total protein from parental, episomal HPV-31 maintaining 
CIN612-9E cells and CIN612-9Ei cells, which are derived from CIN612-9E cells 
but possess integrated viral genomes, then compared total SMC6 protein levels 
(Figure 3.10). Cells maintaining episomal HPV-31 had reduced SMC6 protein 
expression compared to CIN612-9E cells with integrated HPV-31. Densitometry 
revealed that there was a statistically significant increase in SMC6 levels of 
nearly 2-fold in CIN612-9Ei cells as compared to parental CIN612-9E cells. 
These data suggest that integration of viral genomes increases SMC6 
abundance, suggesting that other viral factors may influence SMC6 stability 
when E2 regulatory functions are lost. 
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Figure 3.10. SMC6 expression is greater in integrated HPV-31 CIN612-9E 
compared to parental, episomal HPV-31 CIN612-9E cells. (Left) Total protein 
was isolated from CIN612-9E (episomal HPV-31) and CIN612-9Ei (integrated 
HPV-31) cells and immunoblotting for SMC6 and α-tubulin performed. (Right) 
Densitometry was calculated relative to α-tubulin and statistical significance 
determined by two-tailed Student’s T-test. Experiments were performed three 










































In this study, I investigated SMC6 interactions with HPV proteins and explored 
the role of SMC5/6 during the maintenance phase of the HPV-31 life cycle. I 
found SMC6 is associated with HPV-31 E2 by co-IP and have further identified 
that this interaction requires the E2 transactivation domain. While I cannot rule 
out a contribution of the E2 DNA-binding domain, these data infer that SMC6 
interacts with full-length HPV-31 E2. Importantly, I demonstrated transient 
knockdown of SMC6 and NSE3 resulted in increased HPV-31 replication and 
transcription, implying that SMC5/6 represses these processes during the 
maintenance phase of the viral life cycle. I had speculated that SMC5/6-mediated 
repression of HPV replication may occur through interactions of SMC6 with 
E1/E2 complexes as a mechanism utilized by E2 to prevent over-replication of 
viral genomes. Data indicate this to be an unlikely explanation of the observed 
SMC5/6 repression of viral replication and transcription as I did not find an 
interaction of SMC6 or NSE3 subunits with either HPV-31 E1/E2 complexes or 
E1. However, data showed that the association of SMC6 with E2 was reduced in 
the presence of E1, indicating that SMC6 and E1 compete for E2 binding. This 
possibility is supported in that E2 interactions with both E1 [63-66] and SMC6 
occur via the E2 TAD. Initiation of viral replication requires E2-mediated 
recruitment of E1 to the viral ori and by inhibiting E1 access to the E2 TAD SMC6 
could repress viral replication. My observations that viral replication was 
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increased in cells following depletion of SMC6 and NSE3 provide further 
evidence of this, as decreased E1 competition for E2 binding would enable 
increased E1 recruitment to viral genomes for initiation of replication. Together, 
these data imply that SMC5/6 may repress HPV-31 replication by inhibiting the 
ability of E1 to interact with E2 and subsequently be recruited to viral genomes to 
initiate replication. Whether SMC6 inhibits E2 interactions with other factors to 
mediate repression of the viral replicative program is not currently known.  
 
SMC5/6 associates with host chromatin to mediate homologous recombination 
DNA repair, rescue stalled replication forks [165], and topologically entrap 
extrachromosomal DNA [166]. Additionally, SMC5/6 associates with hepatitis B 
[163, 164] and herpes simplex-1 [164] viral episomes. The purported localization 
of SMC6 to viral episomes and its association with E2 led us to speculate that 
SMC6 may be present on episomal HPV-31 genomes. Indeed, I found SMC6 
and E2 were present on the LCR of HPV-31 episomes at both the 5’ upstream 
E2BS and E2BS located adjacent to the viral ori and early promoter, but not the 
flanking L1 region, indicating specificity for where SMC6 localizes on viral 
genomes. Precisely how SMC5/6 is localized to viral and host DNA remains 
unclear and I wanted to determine if the presence of SMC6 at the viral ori was 
specific, or due to SMC6 non-specifically associating with DNA replication 
origins. I looked for the association of SMC6 and E2 at a known host replication 
origin and found E2 but not SMC6 was present, suggesting that the presence of 
SMC6 at replication origins is selective. E2 is known to associate with host DNA 
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[81, 183, 184] and its consensus sequences are found throughout the host 
genome [183]. I believe that the presence of E2 at the host replication origin is 
likely due to E2 interacting with host factors that are localized to the GM-CSF 
replication origin. Together these data show that SMC6 preferentially associates 
with the LCR of HPV-31 episomes, implying that SMC5/6 repressor functions 
may occur at the viral genome. Mechanistically, repression of HPV-31 replication 
and transcription could involve SMC5/6 influencing the accessibility of viral DNA 
through steric hindrance, recruitment of histone modifying proteins, or via 
interactions with E2 at the viral genome. It is also possible that E2 recruits 
SMC5/6 to viral episomes to regulate viral transcription and replication, as this is 
an established function of E2 [98]. Future work should seek to determine how 
SMC5/6 is targeted to viral DNA and if its repressor functions require localization 
to HPV episomes. 
 
SMC5/6 inhibits the life cycle of hepatitis B (HBV) by repressing transcription of 
the non-replicating, covalently closed circular DNA (cccHBV) intermediate form of 
HBV [163, 164, 168, 169]. My data support an antiviral function for SMC5/6 that 
extends to repression of the HPV-31 replicative program, as SMC6 and NSE3 
depletion enhanced viral replication and transcription. However, as HPV 
episomes are actively transcribed and replicated throughout the viral life cycle 
determining the repressor function of SMC5/6 is less straightforward, as it could 
involve repressing transcription, replication, or both. It is possible that the 
observed increase in viral replication was be due to increased transcription of 
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HPV E1 and E2 following SMC6 and NSE3 knockdown, or vice versa. For 
example, SMC6 depletion resulted in a nearly equivalent increase of viral E2, 
E8^E2, E1 and E1^E4 transcripts and DNA content. It is conceivable that 
increased viral replication could be resultant from higher levels of viral gene 
transcription. While E8^E2 is regarded as a repressor of viral replication and 
transcription whether increased E8^E2 transcript levels correlated with increased 
E8^E2 protein expression is not known. Conversely, SMC5/6 may repress HPV 
replication but not transcription. Should SMC5/6 function as a repressor of HPV 
replication alone then the resulting increase in viral replication following SMC6 
and NSE3 knockdown would generate more viral DNA available to be 
transcribed. Consequently, any observed increase in viral transcript abundance 
would not be resultant from increased gene transcription, but from more viral 
genomes being transcribed. This question could potentially be answered by 
investigating the effects of SMC6 and NSE3 knockdown on viral transcription 
using replication defective viral genomes. HPV replication is E1-dependent and 
genomes that do not produce E1 remain transcriptionally competent but unable 
to replicate [186]. I have made one such HPV-16 E1 mutant genome by insertion 
of a translation termination linker into the E1 ORF (Figure A.1) and future work 
will seek to determine if SMC5/6 influences transcription of non-replicating HPV-
16 during infection.  
 
This study described a role for SMC5/6 as a repressor of the HPV-31 replicative 
program. While in agreement with the findings of studies examining the role of 
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the SMC5/6 complex in hepatitis B and herpes simplex-1 viruses, my findings 
contrast with a previous report in which SMC5/6 was not found to repress  
HPV-31 replication or transcription, but was instead necessary for maintenance 
of viral episomes [173]. This discrepancy has several possible explanations. For 
example, my study primarily relied upon transient depletion of SMC5/6 subunits 
SMC6 and NSE3, as sustained depletion of SMC5/6 subunits has been found to 
be lethal in both non-cancerous and cancerous cells types, as well as result in 
spontaneous DNA damage and chromosomal abnormalities [187]. It is possible 
that all of these factors contributed to findings that utilized stable SMC6 depletion 
(near complete loss) to evaluate the functions of SMC6 in episomal maintaining 
HPV-31 cells. Indeed, my attempts to generate uninfected and infected cell lines 
that tolerated a significant reduction or knockout of NSE3 and SMC6 were 
unsuccessful. This agrees with reports describing a functional SMC5/6 complex 
as essential for cell viability. Cells maintaining episomal HPV-31 that tolerated a 
marginal reduction in NSE3 did not have increased viral DNA content and I 
attribute this to the reasons described above. I speculate that accurately 
examining the effects of SMC5/6 depletion for determining its repressor functions 
during the HPV life cycle may be limited to transient assays.  
 
The absence of NSE3 in complex with E2 suggests that E2 may alter SMC5/6 
complex formation by excluding NSE3. SMC5 and SMC6 form heterodimers 
through binding of their central hinge region while closing of the SMC5/6 complex 
into its characteristic ring shape occurs by bridging of SMC5 and SMC6 terminal 
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globular domains by kleisin subunit NSE4 [147]. Both NSE1 and NSE3 are joined 
to the SMC5/6 complex by binding NSE4. Should E2 interactions with SMC6 
prevent NSE4 binding, the NSE3 association with the SMC5/6 complex would be 
lost. While this possibility accounts for the observed absence of NSE3 I believe it 
to be unlikely. NSE3 is required for SMC5/6 DNA binding [151] and stability of 
the SMC5/6 complex [153]. Therefore, exclusion of NSE3 would require that the 
SMC5/6 complex be stabilized and obtain DNA binding functionality. I do not 
believe that E2 disruption of SMC5/6 complex formation is a likely explanation for 
the absence of NSE3 during E2 IP for multiple reasons. For example, input 
samples from all IP experiments showed that NSE3 abundance was not altered 
in response to co-transfection of cells with E2. Furthermore, in experiments 
where SMC6 was pulled down the amount of NSE3 present in IP samples was 
unchanged when E2 was present. However, without internal loading controls I 
cannot exclude the possibility that low levels of NSE3 were degraded and E2 
sequesters a fraction of SMC6 to form a separate complex that does not include 
NSE3. 
 
HPV E2 proteins have been reported to influence gene expression and protein 
stability of host factors [79, 185], but I do not find that either HPV-31 or HPV-16 
E2 proteins alter SMC6 stability in human keratinocytes. This finding agrees with 
those examining HPV-5, HPV-18, and BPV-1 in that E2 was not found to affect 
SMC6 abundance [173], but contrasts with studies of hepatitis B virus (HBV) 
wherein the master regulatory protein of HBV, HBx, was found to target SMC5/6 
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for degradation shortly after infection [163, 168]. It is possible that this is due to 
differences in the cell type infected and differing roles of SMC5/6 in the life cycles 
of these viruses. While HBV infects non-dividing human hepatocytes, actively 
dividing non-cancerous and cancerous human cell lines have demonstrated that 
sustained loss of SMC5/6 is lethal [187]. The replicative program of HPV is 
dependent upon maintaining the actively dividing state of infected basal 
keratinocytes and therefore, while loss of SMC5/6 may be tolerable in non-
dividing HBV-infected cells, actively dividing HPV infected keratinocytes would 
require a functional SMC5/6 complex for completion of the HPV life cycle.  
 
Loss of E2 function leads to unregulated viral genome transcription and results in 
the derepression of HPV E6 and E7 expression [116-118]. Cells maintaining 
integrated HPV-31 genomes had elevated levels of SMC6 protein as compared 
to parental, episomal HPV-31 maintaining cells and this is potentially explained in 
that the presumed loss of E2-mediated regulation of transcription would result in 
increased E7 expression. E7 is known to stimulate the DNA damage pathway 
[182] and this could potentially cause increased expression of SMC6. 
Alternatively, altered expression of other viral factors may influence SMC6 
expression or stability. However, future studies are needed to determine how 
viral genome integration contributes to increased SMC6 expression.  
 
In conclusion, this study has identified a novel role for SMC5/6 in the life cycle of 
HPV-31. I have demonstrated that depletion of SMC6 and NSE3 result in 
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enhanced viral replication and transcription, inferring that SMC5/6 is a repressor 
of the HPV-31 replicative program. While the repressor function of SMC5/6 in 
hepatitis B virus and herpes simplex-1 viral infections appears to be repression of 
viral DNA transcription, I have not determined if the antiviral functions of SMC5/6 
during HPV infection are specific to replication, transcription, or both. I have 
demonstrated that SMC6 is present on episomal HPV-31 genomes and interacts 
with HPV E2 proteins, but the mechanism by which SMC5/6 represses the viral 
replicative program remains unclear. I hypothesize that SMC5/6-mediated 
repression may involve inhibiting initiation of viral replication through competition 
with E1 for E2 binding. Taken together, this study has demonstrated that the 





















Human papillomaviruses are double-stranded DNA viruses that infect basal 
keratinocytes of the skin and mucosal epithelium [2]. The viral genome encodes 
8 proteins essential to the viral life-cycle, which are designated as early (E), or 
late (L), based upon their temporal expression during the HPV replicative 
program [32]. Among the late proteins are the viral major (L1) and minor (L2) 
capsid proteins that encapsidate the HPV genome. L1/L2 capsids produced in 
vitro have been found to efficiently package HPV genomes (quasivirions; QsV) 
and non-viral DNA (pseudovirions; PsV) not larger than 8 kilobases in size [188-
191]. The ability of HPV capsids to package non-viral DNA represents a unique 
method for transferring plasmid DNA into cells and could provide an efficient and 
advantageous alternative to transfection-based methods.  
 
L1 proteins are capable of spontaneous self-assembly into viral-like particles 
(VLPs) roughly 60nm in diameter that are nearly indistinguishable from native 
virions [20-24] (Figure 5.1). While L2 alone is not capable of forming VLPs its co-
assembly with L1 improves the efficiency of VLP assembly [127]. Initial contact of 
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infectious virions with host cells involves L1 interactions with heparin sulfate 
proteoglycans (HSPGs) in the extracellular matrix and on the cell surface [122]. 
This initial interaction is believed to be essential for infection, as it drives 
conformational changes in the viral capsid that expose L2 to furin proteolytic 
cleavage necessary  for capsid maturation [192]. Although L2 is not required for 
viral entry it is essential for proper genome trafficking within host cells, as DNA 
packaged by L1 alone fails to escape late endosomes [193]. L2 delivers viral 
genomes to the perinuclear space of infected cells via retrograde trafficking by 
the host cell retromer complex, where viral genomes will reside in trafficking 
vesicles until breakdown of the nuclear envelope during mitosis [123, 124]. 
Following breakdown of the nuclear envelope, L2 localizes viral genomes to PML 
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Figure 5.1. Surface-shaded Cryo-EM images of native HPV virions and viral-
like particles. HPV-1 virion isolated from warts (left column), viral-like particle 
(VLP) comprised of L1 alone (middle column) and L1/L2 (right column). Exterior 
(top) and interior (middle) capsid view (bar = 50nm). L1 pentamer (bottom) close-
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Utilizing HPV capsids for gene transfer requires the ability to efficiently produce 
high titers of infectious virions. Initial studies of HPV infection were limited by 
inefficient and labor-intensive methods used for isolating HPV virions. Among 
such methods were isolation of virions from patient tumors or rafted 
keratinocytes, both of which resulted in low yields of virions obtained [194]. The 
discovery that co-transfection of plasmids encoding HPV L1 and L2 capsid 
proteins with DNA of interest (provided it be under 8 kilobases in size) provided a 
new and robust method that was less labor intensive and capable of generating 
high titers of infectious HPV virions [188-190, 195]. This method was further 
refined with the discovery that HPV virions produced in cells overexpressing the 
protease furin were significantly more infectious due to enhanced capsid 
maturation [192, 196]. Despite the development of new and robust methods of 
virion production the efficiency of different cell lines to be infected remained 
variable. This has led to attempts to develop more efficient methods in facilitating 
infection with HPV PsV, such as pre-binding virions to a keratinocyte generated 
extracellular matrix (ECM) prior to infection of target cells [197, 198].  
 
In this study I sought to develop a more efficient method for gene delivery in cells 
that are difficult to transfect and infect using HPV PsV techniques. I describe a 
new HPV L1/L2-based PsV infection method termed suspension-mediated 
infection (SMI) and evaluated the efficiency of SMI in comparison to other 
currently used methods in multiple cell types. SMI was shown to efficiently 
mediates gene transfer in difficult to transfect cell lines, as well as in those cell 
   84 
lines in which other PsV methods fail to produce significant infection. Together, I 
find that SMI is an adaptable and efficient method for facilitating infection of 
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C33A, HaCaT, HeLa, J2 3T3, HepG2, Huh-7, HEK293TT, HEK293TTF, and  
SH-SY5Y were cultured in DMEM/10% FBS. CIN612-9E cells were maintained in 
E-media with mitomycin-C treated J2 cells. N/TERT cells were maintained in 
KSFM supplemented with human EGF and bovine pituitary extract. 
Spontaneously immortalized keratinocyte (NIKS) were cultured in F-media with 




PsV were produced by packaging pmCherry, HPV-31 V5-E2, HA-εCOP, or 
cccHBV(+) (Figure 5.2)  in HPV-16 L1/L2 capsids according to previously 
described methods [196, 199]. Briefly, 20 µg p16sheLL (Figure 5.3) was co-
transfected into HEK293TTF cells with either pmCherry, HPV-31 V5-E2, or HA-
εCOP using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol and cells incubated overnight. The use of p16sheLL avoids undesirable 
self-packaging of the L1/L2 construct. The following day media was changed, 
non-essential amino acids (Gibco) added and cells returned to incubate for an 
additional 24 hours. Two-days post-transfection cells were collected and washed 
in 1X PBS, then 1.5X cell pellet volumes 1X PBS/9.5mM MgCl2 added and cells 
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gently resuspended (e.g. 100µL cell pellet observed in comparison to fluid 
dummy would have 150µL 1X PBS/9.5 mM MgCl2 added, then for all subsequent 
calculations the cell pellet volume (CPV) would be considered as 250 µL). Next, 
maturation buffer was added as follows:  
 
• 1/20th CPV 10% Triton X-100 (Cf = 0.5%)  
• 1/40th CPV 1M (NH4)2SO4 (pH 9; Cf = 25mM) 
• 1/10th CPV 50mM CaCl2 (Cf = 5mM) 
 
Cells were then gently resuspended and left to incubate at 37oC for 48 hours in 
siliconized microcentrifuge tubes. Next, lysates were chilled on ice for 5min, 
followed by centrifugation at 4oC for 5min at 5,000 x g and then PsV containing 
supernatant transferred to fresh siliconized tubes. Original cell pellets were then 
resuspended in 1X cell pellet volumes 1X PBS, then spun again at 4oC and 
combined with the previous supernatant. Combined supernatants were re-
clarified by repeating the centrifugation, then supernatant containing PsV 
transferred to fresh tubes and stored at 4oC. All infection methods tested  
(pre-plated, ECM, SMI) when determining efficiency of infection were performed 
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cccHBV(+) Digestion and Re-ligation 
 
EcoRI digestion of cccHBV(+)/pSP was performed at 37oC to separate 
cccHBV(+) and pSP backbone. EcoRI was then heat inactivated by incubating 
samples at 65oC for 20min. cccHBV(+) episomes were ligated overnight at room 
temperature under dilute conditions to minimize concatemer formation, then 
purified according to previously described methods [200].  
 
Encapsidated DNA Analysis 
 
PsV packaging of cccHBV(+) was evaluated by qPCR and nuclease resistance. 
Samples were undigested (unencapsidated DNA), Proteinase K only (total 
cccHBV(+) DNA in PsV prep), Benzonase only (control for nuclease activity), and 
sequential digestion with Benzonase then Proteinase K (encapsidated DNA). 
Benzonase digestion was performed at 37oC for 30min. Proteinase K only 
digestion was performed at 50oC for 30min, then Proteinase K inactivated using 
PMSF. Double digest was performed by first digesting with Benzonase, followed 
by Proteinase K digestion and inactivation as described above. qPCR Ct values 
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Figure 5.2. HBV cccDNA. The 3.2kb HBV cccDNA episome functions as the 
transcriptional template for production of viral mRNA encoding the polymerase 
(P), HBx transcription factor (red), pre-core (HBeAg), core (HBcAg), large (L), 
medium (M), and small (S) surface antigens.  
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Figure 5.3. p16sheLL. The HPV-16 p16sheLL vector encodes both major (L1) 
and minor (L2) capsid proteins used to package viral and non-viral DNA. This 






   90 
Pre-plated Infection 
 
Cells were plated without pre-generated ECM prior to infection, allowed to fully 
adhere to plates and then PsV added. Twenty-four hours later media was 
replaced and fluorescence observed at twenty-four, forty-eight, and seventy-two 
hours post-infection. Efficiency of infection was determined by the percent of 
intracellular red fluorescence.  
 
Extracellular Matrix (ECM) Generation & Infection 
 
ECM was produced according to previously described methods [198]. To 
generate ECM cells were grown to confluence, then washed with 1X PBS and 
treated with ECM-buffer (170 mM NH4OH, 0.5% Triton X-100, 1X PBS). 
Following visual confirmation that cell bodies had been removed using light 
microscopy, ECM buffer was removed and then gently washed three times with 
1X PBS. PsV and media (containing FBS) were added to wells and PsV allowed 
to adhere to ECM overnight at 37oC. The following day, media and unbound PsV 
were removed and ECM gently washed with 1X PBS, then standard culture 
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Suspension-mediated Infection (SMI) 
 
SMI was performed by mixing cells and PsV in suspension at the time of plating, 
allowing PsV to bind to cells in suspension prior to adhesion to plates and in the 
absence of ECM, then cells were incubated overnight at 37oC (Figure 5.4). The 
following day, media containing unbound virus was removed and cells returned 
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Figure 5.4. Suspension-mediated infection (SMI). Schematic representation of 
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Immunoprecipitation & Immunoblotting 
 
HEK293TT, N/TERT and SH-SY5Y cells were infected with mCherry, HPV-31 
V5-E2, or HA-εCOP PsV. Forty-eight hours later, cells were lysed in 0.5% NP-
40/150mM NaCl/50 mM Tris-HCl (pH 8)/10% glycerol and protease inhibitor 
cocktail (Sigma). Samples were then rotated for 1hr at 4oC after the addition of 
4μL benzonase (Millipore), then spun for 10min at 4oC and supernatant collected. 
IP was performed by incubation of lysates with Protein A/G slurry and either 
rabbit anti-V5 (Cell Signal Technologies) or mouse 12CA5A1 anti-HA antibodies. 
Beads were then washed in lysis buffer and boiled in 2X Laemmli buffer. SDS-






Immortalized non-cancerous keratinocyte cell lines such as N/TERT and HaCaT 
are commonly used for examination of the HPV life cycle. We first sought to 
determine efficiency and optimize conditions for infection of these cell lines. PsV 
packaged with a plasmid encoding mCherry red protein were used to calculate 
infection efficiency as the percentage of red fluorescent cells, which indicated 
nuclear uptake and gene expression of plasmids. We first titrated PsV by 
infecting HEK293TT cells with 1-10µL of virus to identify the volume of PsV that 
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resulted in roughly 90-95% mCherry positive cells. Two days post infection we 
observed 100% infection with 5µL and 10µL volumes, which indicated PsV were 
in excess (Figure 5.5A), while 3µL resulted in 90-95% mCherry positive cells. All 
subsequent infections used 3µL mCherry PsV. Several independently produced 
mCherry PsV batches demonstrated consistent infectivity, indicating equivalent 
titers are produced between batches. Infection efficiency of N/TERT and HaCaT 
cells were significantly reduced compared to HEK293TT and HeLa cells (Figure 
5.5B). Low infectivity of N/TERT cells is consistent with previously published 
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Figure 5.5.  mCherry PsV titration and infection. (A) mCherry PsV was titered 
by adding the indicated volumes of virus to HEK293TT cells and evaluating 
intracellular red fluorescence 48 hours later. (B) Indicated cell lines were cultured 
overnight before infection with 3µL mCherry PsV and intracellular red 
fluorescence examined 48 hours later. All experiments were performed at least 3 







































































































Furin cleavage enhances infectivity
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During infection HPV binds to factors in the cellular ECM prior to interacting with 
cell surface receptors, which is believed to induce conformational changes in the 
capsid that promote internalization [122]. HPV has been found to bind epithelial 
cell derived ECM with the greatest efficiency [197, 198] and some labs have 
used ECM to study HPV infection. We questioned whether infection efficiency of 
HaCaT and N/TERT cells could be increased by pre-binding of PsV to 
keratinocyte ECM prior to infection. HaCaT, N/TERT and NIKS cells were grown 
to confluence and ECM generated by removing cells using NH4OH as described 
elsewhere [198]. mCherry PsV were allowed to adhere to the ECM overnight and 
the following day cells were added. Keratinocyte ECM promoted increased 
infectivity in both HaCaT and N/TERT cells as compared to infections performed 
without ECM (Figure 5.6). Efficient infection of N/TERT cells using ECM requires 
that FBS is included in the media during incubation of PsV with the ECM. To 
determine if ECM could be used to promote infection of non-keratinocyte cell 
lines I tested whether HepG2, Huh-7, or N/TERT ECM could be used to promote 
infection of HepG2 and Huh-7 cells. Roughly 100% of control HEK293TT cells 
were infected without ECM while no infection was observed in HepG2 cells with 
or without ECM (Figure 5.7). Huh-7 cells demonstrated low infectivity without 
ECM or with Huh-7 ECM, but nearly 80% infection was observed when Huh-7 
cells were infected using N/TERT ECM. 
 
 
   97 
 
Figure 5.6. Keratinocyte ECM enhances HaCaT and N/TERT infection. ECMs 
from indicated cells at the bottom of each graph were incubated with mCherry 
PsV overnight in FBS containing media. Unbound PsV were removed, fresh 
media and HaCaT (A) or N/TERT (B) cells added to ECM. Cells infected without 
ECM (none) were plated the previous day and infections were performed at the 
same time. Infection efficiency was determined by the percent of intracellular red 
fluorescence. All experiments were performed at least 3 independent times and 
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Figure 5.7. mCherry PsV hepatocyte infections. ECM from HepG2, Huh-7 or 
N/TERT cells were incubated with mCherry PsV overnight. Unbound PsV were 
removed, ECM washed and cells added to ECM. Control HEK293TT, HepG2 and 
Huh-7 cells infected without ECM (No ECM) were plated the previous day and 
infections performed at the same time as ECM infections. Infection efficiency was 
determined by the percent of intracellular red fluorescence 72hrs post-infection. 
All experiments were performed at least 3 independent times and values shown 
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The established model of HPV infection involves interactions of viral capsid 
proteins with cellular factors in the ECM and on the cell surface to mediate 
internalization of the virus [122]. I speculated that infecting cells in suspension 
may enhance infection by enabling increased PsV access to a larger cell surface 
area and more viral attachment points for stimulating internalization. I piloted 
trials of suspension-mediated infection (SMI) in which trypsinized cells are 
exposed to PsV immediately before plating (Figure 5.4). SMI infection efficiency 
was increased or equivalent to cells plated prior to infection (Figure 5.8). N/TERT 
and Huh-7 cells demonstrate low infection efficiency without ECM but were 
efficiently infected with PsV using SMI. HepG2 cells were uninfectable, even with 
ECM by PsV but roughly 100% susceptible to infection by SMI. Representative 
images of SMI infected cells are shown in Figure 5.9 with differential interference 
contrast white light images on left and mCherry PsV infected cells on right. Our 
lab has previously observed that incubating various ECM in different media can 
influence infection efficiency. I speculated that this might also enhance infection 
efficiency when using SMI. I found that SMI efficiency in various cell lines could 
be significantly increased based on the use of different media (Table A.7). For 
example, N/TERT cells infected in KSFM with mCherry PsV showed marginal 
infection efficiency using SMI, but when SMI was used on N/TERT cells in F-
media, efficiency increased from approximately 10% to roughly 80% (Figure 
5.10). N/TERT cells are able to proliferate in serum containing media and this 
induces morphological change, however cells begin reverting back within roughly 
30 minutes of placement into serum-free KSFM (Figure 5.11). SMI efficiency in 
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HepG2 and Huh-7 cells is also influenced by media, with E-media producing the 
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Figure 5.8. SMI efficiently infects diverse cell types. Summary comparison of 
cell infection efficiency at 72hrs post-infection with mCherry PsV using media 
found most efficient for infecting each cell type. Cells were plated without ECM 
prior to infection (grey), or infected by SMI (black). Data are percent of cells 
positive for mCherry fluorescence. All experiments were performed at least 3 
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Figure 5.9. SMI infection immunofluorescence. Immunofluorescence of 
CIN612-9E, HepG2 and SH-SY5Y cells 72 hours after infection by SMI with 
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Figure 5.10. Media influences SMI efficiency. N/TERT, HepG2, and Huh-7 
cells were infected with mCherry PsV without ECM (control), or using SMI in 
different media and fluorescence analyzed at 24, 48, and 72hrs. All experiments 
were performed at least 3 independent times and values are expressed as the 
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Figure 5.11. FBS influences N/TERT cell morphology. Morphology of N/TERT 
cells observed after plating cells into either KSFM (panel 1) or F-media 
containing FBS (panel 2), then N/TERT cells 15min after changing F-media to 
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Given that efficient infection of difficult to transfect cell lines (e.g. N/TERT,  
SH-SY5Y) was demonstrated and PsV capsids can package plasmid DNA up to 
8 kilobases in size, I sought to determine if PsV infection using SMI could be 
used as an alternative to transfection with delivering different plasmids. Using 
SMI, HEK293TT, N/TERT and SH-SY5Y cells were infected with either mCherry, 
HPV-31 V5-E2, or HA-εCOP PsV. Two days post-infection, cells were lysed and 
immunoprecipitated with antibody to V5 or HA. Successful infection and plasmid 
expression was observed in all cell lines (Figure 5.12A-D). Therefore, SMI 
constitutes an employable method to mediate efficient plasmid delivery and an 
alternative to transfection-based methods. SMI and ECM based methods both 
efficiently infect N/TERT cells and these methods were compared for 
heterologous protein expression. N/TERT cells were infected with V5-E2 PsV 
either by SMI or ECM method, then two days post-infection lysates were 
immunoblotted with V5 antibody. Intriguingly, SMI produced greater V5-E2 
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Figure 5.12. SMI efficiently delivers genes for protein expression. (A) 
HEK293TT cells were infected using SMI with HPV-31 V5-E2 PsV for two days, 
lysed and immunoprecipitated with rabbit anti-V5 antibody, then immunoblotted 
with mouse anti-V5 antibody. (B) SH-SY5Y cells were infected with HA-εCOP 
PsV for two days, lysed, and immunoprecipitated with mouse 12CA5A1 anti-HA 
antibody and immunoblotted with mouse HA-7 anti-HA. (C) As in A, but with 
N/TERT cells.  (D) N/TERT cells were infected with V5-E2 PsV either by SMI or 
ECM methods. Two days following infection, cells were harvested and 
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Having demonstrated PsV can efficiently package different plasmids and infect 
HepG2 and Huh-7 hepatocytes, I wanted to determine if PsV could be used to 
package non-HPV viral DNA. Hepatitis B virus (HBV) utilizes a non-replicating, 
3.2kb episomal form of the viral genome termed covalently closed circular DNA 
(cccDNA) to serve as a transcriptional template during infection [203]. I 
questioned if cccDNA could be packaged into PsV to provide an efficient method 
for directly delivering cccDNA into the nuclei of hepatocytes for studying HBV 
infection. I examined whether PsV had packaged HBV cccDNA(+) DNA by 
digesting samples with Benzonase and compared this to undigested samples. I 
observed roughly 2-fold more cccDNA(+) was packaged (nuclease resistant) 
than not packaged (undigested)(Figure 5.13). Benzonase only control digestion 
resulted in no signal amplification by qPCR, indicating complete digestion of 
unprotected DNA. These data suggest HPV PsV are capable of packaging 
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Figure 5.13. PsV package HBV cccDNA(+). Undigested PsV samples were 
used to determine unencapsidated (unpackaged) DNA. Nuclease digestion was 
performed to degrade unencapsidated DNA and Proteinase K digestion used to 
degrade Benzonase and liberate encapsidated (packaged) DNA. Benzonase 
only (control) was used to confirm nuclease activity. qPCR Ct values were 
normalized to total cccHBV(+) DNA present in PsV viral preps and fold change 
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5.5.4 Discussion 
 
The use of L1 and L2 proteins for production of infectious virions provides an 
efficient tool for packaging and delivering non-viral DNA by infection. However, 
while certain cell lines are readily infected by HPV capsids many others 
demonstrate low or variable infectability. mCherry packaged HPV pseudovirions 
(PsV) were used to evaluate the efficiency of different infection methods and 
describe a new method to mediate efficient gene transfer using PsV.   
 
The ECM is comprised of different cellular factors that are involved in HPV 
capsid maturation [122]. Maturation of HPV capsids is believed to be driven by 
interactions with various cellular proteases of the ECM and heparin sulfate 
proteoglycans prior to internalization. I observed that keratinocyte ECM can be 
used to increase the infection efficiency of HaCaT and N/TERT cells provided 
that FBS is present. This is in agreement with others in that keratinocyte ECM 
can enhance HPV infection [197]. It is possible that the ECM method increases 
efficiency of infection in HaCaT and N/TERT cells by enhancing viral capsid 
maturation prior to cell contact. Additionally, the requirement for FBS to facilitate 
efficient N/TERT infection using ECM indicates that factors present in FBS 
enhance PsV maturation or binding with cells. While infection efficiency of some 
cell lines can be increased using keratinocyte ECM this is not always the case, 
such as with HepG2 cells. Why HepG2 cells are only infectable using SMI 
remains unclear, but there are several possible explanations. One possibility is 
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that HepG2 cells may produce factors that are inhibitory to infection which are 
proteolytically cleaved by trypsin when cells are suspended prior to infection by 
SMI. This possibility could be explored by removing HepG2 cells from plates 
using EDTA instead of trypsin, then infecting with mCherry PsV using SMI. 
 
The requirement for HPV capsid interactions with the ECM for infection is 
challenged in the context of the SMI method. SMI mixes cells and PsV in 
suspension and results in efficient infection of multiple cell types, including those 
resistant to transfection (e.g. SH-SY5Y) or found uninfectable with or without 
ECM (e.g. HepG2). This is potentially explained by exposure of cells to PsV in 
suspension enabling increased cellular surface access or exposure to factors on 
the cell undersurface not normally accessible until mitosis as cells release from 
the culture plate. I believe that greater internalization of virions also provides a 
possible explanation as to why SMI was found more effective than ECM in 
delivering plasmids to overexpress protein. Why different media influenced 
infection efficiency of SMI may be explained by each media providing distinct 
factors that stimulate or inhibit infection. Alternatively, different media influencing 
the growth rates of cells could influence how quickly cells become infected. Viral 
entry into the nucleus requires breakdown of the nuclear envelope during cell 
division [124] and faster growing cells would enable more rapid access of the 
virus to the nucleus, with the opposite true for those with slowed growth rates.  
Multiple limitations are associated with transfection as a method for gene transfer 
and studying HPV biology. Transfected DNA is released into the cytoplasm and 
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detected by cGAS, resulting in cGAS-STING pathway activation [204, 205]. 
Conceivably, this could reduce plasmid expression at both transcriptional and 
translational levels. Variable transfection efficiency of different cell types makes 
reliable delivery and expression of plasmids challenging. Furthermore, the cost 
and toxicity of certain reagents highlights additional drawbacks of using 
transfection. These drawbacks are not limited to protein overexpression but also 
manifest when studying HPV biology. HPV genomes are not exposed to antiviral 
DNA sensors of the cytoplasm during natural infection and accurately studying 
HPV biology necessitates the avoidance of triggering pathways that would 
otherwise not be stimulated. Additionally, many keratinocytes used for studying 
HPV infection have low transfection efficiency. Together, the limitations 
associated with transfection-based approaches when studying HPV biology and 
for gene delivery highlight the need for alternative methods of gene transfer. 
 
Transfection-based methods also preclude accurately studying certain aspects of 
hepatitis B virus (HBV) biology. HBV is trafficked to the nuclei of infected 
hepatocytes in the absence of cytoplasmic exposure and it is within the nucleus 
that HBV relaxed circular DNA is converted into cccDNA [203]. cccDNA is the 
persistent form of the virus that remains within infected hepatocytes and its 
elimination is necessary for curing chronic HBV infection, but current antiviral 
therapies do not target cccDNA [206]. Therefore, the ability to quickly and 
efficiently deliver cccDNA into the nucleus of cells could provide a novel 
approach for studying cccDNA in order to identify new therapeutic targets. 
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Further research is required to determine if PsV packaged cccDNA can be used 
to deliver transcriptionally active cccDNA into hepatocytes. 
 
The ability of HPV capsids to package different plasmids could impart 
advantages to traditional transfection methods. I have shown that PsV are able to 
package both pCI and pcDNA3 based vectors. Furthermore, I have shown that 
HPV PsV are capable of packaging hepatitis B virus (HBV) cccDNA, which 
provides an intriguing new method for studying HBV infection. Additionally, I have 
shown efficient infection of difficult to transfect and infect cells using SMI. In 
conclusion, HPV PsV-mediated infections provide a more accurate method for 
studying HPV infection, as well as a versatile technique that can be used to 
efficiently deliver plasmids in different cell types and I have described a novel 

















Figure A.1. Generating replication defective HPV-16 E1 mutant genomes. 
(A) Site-directed mutagenesis utilized primers to insert a translation termination 
linker (TTL) into the E1 open reading frame, which would remove a KasI 
restriction endonuclease site for enhanced colony screening. (B) Purified DNA 
was KasI endonuclease digested and run on 0.8% agarose gels. (C) NCBI 
sequence BLAST of wild-type HPV-16 and prospective HPV-16 E1 mutant 
genome from colony 10. (D) Sequencing results of DNA purified from colony 10 








HPV-16/pMC E1 mutant screening.
HPV-16 E1wt: 250 bp, 3.8 kb, 7.8 kb






















(5627) KasI(5610-5648) E1 TTL
HPV-16/pMC
(11,988 bp)
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Table A.1. E2 host interacting factors. 
UniProt ID Protein Name Reference 
Q13227 AMF1 G-protein pathway suppressor 2 [207] 
P10275 AR androgen receptor [208] 
P38398 BRCA1 breast cancer type 1 susceptibility protein [209] 
O60885 BRD4 Bromodomain-containing protein 4 [170, 210-212] 
Q07021 C1QBP complement component 1 Q subcomponent-binding protein [213] 
Q14790 CASP8 Caspase-8 [214] 
Q92793 CBP CREB-binding protein [215] 
Q12834 CDC20 cell division cycle protein 20 [216] 
Q9UM11 CDH1 Fizzy-related protein homolog [216] 
P49715 CEBPA CCAAT/enhancer-binding protein alpha [217] 
P17676 CEBPB CCAAT/enhancer-binding protein beta [217] 
O15519 cFLIP FADD-like apoptosis regulator [218] 
Q8TD26 CHD6 chromodomain-helicase-DNA-binding protein 6 [219] 
Q96FC9 CHLR1 DEAD/H box polypeptide 11 [85] 
P09496 CLTA clathrin light chain A [220] 
O95639 CPSF4 cleavage and polyadenylation specificity factor subunit 4 [221] 
Q13618 CUL3 Cullin-3 [222] 
Q09472 p300 histone acetyltransferase p300 [223] 
Q96L91 P400 E1A binding protein p400 [212] 
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Table A.1. E2 host interacting factors (cont.). 
UniProt ID Protein Name Reference 
P21802 FGFR2 Fibroblast growth factor receptor 2 [224] 
P22607 FGFR3 Fibroblast growth factor receptor 3 [225] 
Q9Y3R0 GRIP1 Glutamate receptor-interacting protein 1 [226] 
Q00403 GTF2B transcription initiation factor IIB [220] 
Q13547 HDAC1 histone deacetylase 1 [227] 
Q92769 HDAC2 histone deacetylase 2 [227] 
O15379 HDAC3 histone deacetylase 3 [113, 227] 
O95235 KIF20A Kinesin-like protein KIF20A [220] 
O00505 KPNA3 Importin subunit alpha-3 [228] 
O15131 KPNA5 Importin subunit alpha-6 [228] 
Q00987 MDM2 E3 ubiquitin-protein ligase Mdm2 [229] 
P55209 NAP1 Nucleosome assembly protein 1-like 1 [230] 
O75376 NCoR Nuclear receptor corepressor 1 [113] 
P48552 NRIP Nuclear receptor-interacting protein 1 [231] 
Q13416 ORC2 Origin recognition complex subunit 2 [175] 
P09874 PARP1 Poly[ADP-ribose] polymerase 1 [232] 
Q92831 PCAF Histone acetyltransferase KAT2B [233] 
Q9UM63 PLAL1 Zinc finger protein PLAGL1 [226] 
P53350 PLK1 Serine-threonine-protein kinase PLK1 [234] 
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Table A.1. E2 host interacting factors (cont.). 
UniProt ID Protein Name Reference 
P27694 RPA1 Replication protein A [235] 
Q15047 SETDB1 Histone-lysine N-methyltransferase SETDB1 [227] 
Q07955 SRSF1 Serine/arginine-rich splicing factor 1 [213, 236] 
Q01130 SRSF4 Serine/arginine-rich splicing factor 2 [236] 
Q16629 SRSF5 Serine/arginine-rich splicing factor 5 [236] 
Q13309 SKP2 S-phase kinase-associated protein 2 [237] 
P51531 SMARCA2 Probable global transcription activator SNF2L2 [106] 
P51532 SMARCA4 Transcription activator BRG1 [238] 
Q12824 SMARCB1 
SWI/SNF-related matrix-associated 
actin-dependent regulator of 
chromatin subfamily B member 1 
[238] 
Q8IY18 SMC5 Structural maintenance of chromosomes protein 5 [170] 
Q96SB8 SMC6 Structural maintenance of chromosomes protein 6 [170] 
Q16637 SMN1 Survival motor neuron protein [239] 
P08612 SNRNP70 U1 small nuclear ribonucleoprotein 70kDa [213] 
P08047 SP1 Transcription factor Sp1 [240] 
P21675 TAF1 Transcription initiation factor TFIID subunit 1 [241, 242] 
P49848 TAF6 Transcription initiation factor TFIID subunit 6 [241] 
Q15545 TAF7 Transcription initiation factor TFIID subunit 7 [243] 
Q86VP1 TAX1BP1 Tax1-binding protein 1 [244] 
P20226 TBP TATA-box-binding protein [241, 243, 245] 
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Table A.1. E2 host interacting factors (cont.). 
UniProt ID Protein Name Reference 
P04637 P53 Cellular tumor antigen p53 [246] 
Q00403 TFIIB Transcription initiation factor IIB [247] 
Q9Y5LO TNPO3 Transportin-3 [213] 
Q92547 TOPBP1 DNA-topoisomerase 2-binding protein 1 [248] 
P11387 TopoI DNA topoisomerase 1 [249] 
P62995 TRA2B Transformer-2 protein homolog beta [213] 
Q13263 TRIM28 Transcription intermediary factor 1-beta [227] 
P63279 UBC9 SUMO-conjugating enzyme [250] 
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Table A.2. Cell lines. 
Cell Line 
 
Media Notes Source 
C33A 
 
DMEM/10% FBS  D. Lowy 
CIN612-9E E-MEDIA co-culture w/J2 
 
L. Laimins 








DMEM/10% FBS 200 ug/mL G418 n/a 




DMEM/10% FBS  R. Roden 
HeLa 
 
DMEM/10% FBS  D. Lowy 
HepG2 DMEM/10% FBS 
 
 H. Guo 
Huh-7 
 
DMEM/10% FBS  H. Guo 
J2 3T3 
 














NIKS F-MEDIA co-culture w/J2 B. Allen-
Hoffman 
 
NIKS/HPV-31 F-MEDIA co-culture w/J2; 
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Table A.3. Plasmids. 
Plasmid VECTOR Resistance (Bacterial/Human) SOURCE 
pcDNA3 pcDNA3 Amp/G418 Addgene 
pmCherry pmCherry Amp/G418 C. Lorson 
HPV-16 L1/L2 
(codon-optimized) p16sheLL Amp/Blasticidin J. Schiller 
FLAG-SMC6 
(NM_001142286) pcDNA3 Amp/G418 GenScript 
HPV-31 HA-E1 
(codon-optimized) pcDNA3 Amp/G418 A. McBride 
HPV-31 FLAG-E2 




pcDNA3 Amp/G418 [174] 
HPV-31 V5-E2 
(codon-optimized) pCIneo-V5 Kan/G418 T. Gilson 
HA-εCOP pcDNA3 Amp/G418 T. Gilson 
MISSION shGFP 
(SHC002) pLKO.1 Amp/G418 Sigma-Aldrich 
MISSION shNSE3 
(TRCN0000115778) pLKO.1 Amp/G418 Sigma-Aldrich 
MISSION shSMC6 
(TRCN0000219949) pLKO.1 Amp/G418 Sigma-Aldrich 
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Table A.4. siRNAs.  




















siNSE3 NSE3 IDT (hs.Ri.NDNL2.13.1) exon 1
(NM_138704) 



















   121 
Table A.5. Antibodies.  
Antibody Target Source/Catalog # NOTES 
Rabbit α-goat IgG2 
(control antibody) 
heavy &  







α-tubulin Sigma-Aldrich (T6199) 1:5000
(WB) 
Mouse M2 α-FLAG1 





Mouse 12CA5A1 α-HA1 




















Rabbit α-HPV-31 E22 
(1o antibody) HPV-31 E2 
[175] 
(PAC 10008; final) 10μL
(ChIP) 
Rabbit α-NDNL22 

















Rat α-HPV-31 E11 





mouse α-rabbit IgG 




donkey α-mouse IgG 
(2o antibody) 
heavy &  




goat α-mouse IgG 










   122 
Table A.6. Primers. 
PRIMER SET SEQUENCE (5’>3’) REFERENCE 
HPV-31 L1 F: cacctccctcaggttctttg R: atggatcttccttgggcttt [175] 
HPV-31 E2BS (5’) F: cctgctcctcccaatagtca R: ggaccgggtgtacaactttt [175] 
HPV-31 E2BS (3’) F: ttgtgcaaacctacagacgcca R: agcttagttcatgcaatttccgagg n/a 
GM-CSF F: acccagtccacctcactaat R: ttggtttcctttcagagcct [251] 
HPV-31 E1 F: agccacccaaattacgtagcac R: tcgctaatgtttgacattcctgttc n/a 
HPV-31 E1^E4 F: tgttaatgggctcatttggaa R: ggttttggaattcgatgtgg [176] 
HPV-31 E2 F: agcgttgtcagtatcaaaggc R: gctgcattgtccagtcctcat n/a 
HPV-31 E8^E2 F: gtggaaacgcagcagatggta R: ttcgatgtggtggtgttgttg n/a 
SMC6 F: gttggcgaaatgaaccggag R: cttgtcttggccttttggca n/a 
NSE3 F: ctcatcaacaccctggagcc R: atcatcaggaggcccgtagt n/a 
β-actin F: gaggcactcttccagccttc R: cggatgtccacgtcacactt [175] 
GAPDH F: cgcaggccggatgtgttc R: acgaccaaatccgttgactcc n/a 
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Table A.7. SMI media. Media used for standard cell culture and media found 
most effective for mediating high infection efficiency using SMI. 
 
CELL LINE STANDARD MEDIA SMI MEDIA 
CaSki DMEM/10% FBS DMEM/10% FBS 
CIN612-9E E E 
HaCaT DMEM/10% FBS F 
HaCaT DMEM/10% FBS F 
HEK293TT DMEM/10% FBS DMEM/10% FBS 
HEK293TTF DMEM/10% FBS DMEM/10% FBS 
HeLa DMEM/10% FBS F 
HepG2 DMEM/10% FBS E 
HFK KSFM F 
Huh-7 DMEM/10% FBS E 
J2 DMEM/10% FBS F 
N2A DMEM/10% FBS F 
NIKS F F 
N/TERT KSFM F 
SH-SY5Y DMEM/10% FBS DMEM/10% FBS 






   124 
 REFERENCES 
 
1. Lopez-Bueno, A., et al., Concurrence of Iridovirus, Polyomavirus, and a 
Unique Member of a New Group of Fish Papillomaviruses in Lymphocystis 
Disease-Affected Gilthead Sea Bream. J Virol, 2016. 90(19): p. 8768-79. 
2. Ozbun, M.A., Extracellular events impacting human papillomavirus 
infections: Epithelial wounding to cell signaling involved in virus entry. 
Papillomavirus Res, 2019. 7: p. 188-192. 
3. zur Hausen, H., Papillomaviruses and cancer: from basic studies to 
clinical application. Nat Rev Cancer, 2002. 2(5): p. 342-50. 
4. Rector, A. and M. Van Ranst, Animal papillomaviruses. Virology, 2013. 
445(1-2): p. 213-23. 
5. de Villiers, E.M., et al., Classification of papillomaviruses. Virology, 2004. 
324(1): p. 17-27. 
6. de Villiers, E.M., Cross-roads in the classification of papillomaviruses. 
Virology, 2013. 445(1-2): p. 2-10. 
7. Gheit, T., Mucosal and Cutaneous Human Papillomavirus Infections and 
Cancer Biology. Front Oncol, 2019. 9: p. 355. 
8. Haedicke, J. and T. Iftner, Human papillomaviruses and cancer. Radiother 
Oncol, 2013. 108(3): p. 397-402. 
9. de Martel, C., et al., Worldwide burden of cancer attributable to HPV by 
site, country and HPV type. Int J Cancer, 2017. 141(4): p. 664-670. 
   125 
10. Schiffman, M. and N. Wentzensen, Human papillomavirus infection and 
the multistage carcinogenesis of cervical cancer. Cancer Epidemiol 
Biomarkers Prev, 2013. 22(4): p. 553-60. 
11. Chesson, H.W., et al., The estimated lifetime probability of acquiring 
human papillomavirus in the United States. Sex Transm Dis, 2014. 41(11): 
p. 660-4. 
12. Serrano, B., et al., Epidemiology and burden of HPV-related disease. Best 
Pract Res Clin Obstet Gynaecol, 2018. 47: p. 14-26. 
13. Ho, G.Y., et al., Natural history of cervicovaginal papillomavirus infection 
in young women. N Engl J Med, 1998. 338(7): p. 423-8. 
14. Cason, J., et al., Perinatal infection and persistence of human 
papillomavirus types 16 and 18 in infants. J Med Virol, 1995. 47(3): p. 209-
18. 
15. Rombaldi, R.L., et al., Perinatal transmission of human papilomavirus 
DNA. Virol J, 2009. 6: p. 83. 
16. Lee, S.M., et al., Risk of vertical transmission of human papillomavirus 
throughout pregnancy: a prospective study. PLoS One, 2013. 8(6): p. 
e66368. 
17. Bouvard, V., et al., A review of human carcinogens--Part B: biological 
agents. Lancet Oncol, 2009. 10(4): p. 321-2. 
18. Gallagher, K.E., D.S. LaMontagne, and D. Watson-Jones, Status of HPV 
vaccine introduction and barriers to country uptake. Vaccine, 2018. 36(32 
Pt A): p. 4761-4767. 
   126 
19. Toh, Z.Q., et al., Recombinant human papillomavirus nonavalent vaccine 
in the prevention of cancers caused by human papillomavirus. Infect Drug 
Resist, 2019. 12: p. 1951-1967. 
20. Roden, R.B., et al., In vitro generation and type-specific neutralization of a 
human papillomavirus type 16 virion pseudotype. J Virol, 1996. 70(9): p. 
5875-83. 
21. Kirnbauer, R., et al., Papillomavirus L1 major capsid protein self-
assembles into virus-like particles that are highly immunogenic. Proc Natl 
Acad Sci U S A, 1992. 89(24): p. 12180-4. 
22. Kirnbauer, R., et al., Efficient self-assembly of human papillomavirus type 
16 L1 and L1-L2 into virus-like particles. J Virol, 1993. 67(12): p. 6929-36. 
23. Hagensee, M.E., N. Yaegashi, and D.A. Galloway, Self-assembly of 
human papillomavirus type 1 capsids by expression of the L1 protein 
alone or by coexpression of the L1 and L2 capsid proteins. J Virol, 1993. 
67(1): p. 315-22. 
24. Hagensee, M.E., et al., Three-dimensional structure of vaccinia virus-
produced human papillomavirus type 1 capsids. J Virol, 1994. 68(7): p. 
4503-5. 
25. Harper, D.M., et al., Sustained efficacy up to 4.5 years of a bivalent L1 
virus-like particle vaccine against human papillomavirus types 16 and 18: 
follow-up from a randomised control trial. Lancet, 2006. 367(9518): p. 
1247-55. 
   127 
26. Villa, L.L., et al., Prophylactic quadrivalent human papillomavirus (types 6, 
11, 16, and 18) L1 virus-like particle vaccine in young women: a 
randomised double-blind placebo-controlled multicentre phase II efficacy 
trial. Lancet Oncol, 2005. 6(5): p. 271-8. 
27. Dillner, J., et al., Four year efficacy of prophylactic human papillomavirus 
quadrivalent vaccine against low grade cervical, vulvar, and vaginal 
intraepithelial neoplasia and anogenital warts: randomised controlled trial. 
BMJ, 2010. 341: p. c3493. 
28. Kang, W.D., H.S. Choi, and S.M. Kim, Is vaccination with quadrivalent 
HPV vaccine after loop electrosurgical excision procedure effective in 
preventing recurrence in patients with high-grade cervical intraepithelial 
neoplasia (CIN2-3)? Gynecol Oncol, 2013. 130(2): p. 264-8. 
29. Madeleine, M.M., et al., Natural Antibodies to Human Papillomavirus 16 
and Recurrence of Vulvar High-Grade Intraepithelial Neoplasia (VIN3). J 
Low Genit Tract Dis, 2016. 20(3): p. 257-60. 
30. Swedish, K.A., S.H. Factor, and S.E. Goldstone, Prevention of recurrent 
high-grade anal neoplasia with quadrivalent human papillomavirus 
vaccination of men who have sex with men: a nonconcurrent cohort study. 
Clin Infect Dis, 2012. 54(7): p. 891-8. 
31. Buck, C.B., P.M. Day, and B.L. Trus, The papillomavirus major capsid 
protein L1. Virology, 2013. 445(1-2): p. 169-74. 
   128 
32. Burley, M., S. Roberts, and J.L. Parish, Epigenetic regulation of human 
papillomavirus transcription in the productive virus life cycle. Semin 
Immunopathol, 2020. 42(2): p. 159-171. 
33. Desaintes, C. and C. Demeret, Control of papillomavirus DNA replication 
and transcription. Semin Cancer Biol, 1996. 7(6): p. 339-47. 
34. del Mar Pena, L.M. and L.A. Laimins, Differentiation-dependent chromatin 
rearrangement coincides with activation of human papillomavirus type 31 
late gene expression. J Virol, 2001. 75(20): p. 10005-13. 
35. Doorbar, J., The E4 protein; structure, function and patterns of expression. 
Virology, 2013. 445(1-2): p. 80-98. 
36. Graham, S.V., Human papillomavirus: gene expression, regulation and 
prospects for novel diagnostic methods and antiviral therapies. Future 
Microbiol, 2010. 5(10): p. 1493-506. 
37. Nakahara, T., et al., Human papillomavirus type 16 E1^E4 contributes to 
multiple facets of the papillomavirus life cycle. J Virol, 2005. 79(20): p. 
13150-65. 
38. Peh, W.L., et al., The viral E4 protein is required for the completion of the 
cottontail rabbit papillomavirus productive cycle in vivo. J Virol, 2004. 
78(4): p. 2142-51. 
39. Wilson, R., F. Fehrmann, and L.A. Laimins, Role of the E1^E4 protein in 
the differentiation-dependent life cycle of human papillomavirus type 31. J 
Virol, 2005. 79(11): p. 6732-40. 
   129 
40. Wilson, R., et al., The full-length E1E4 protein of human papillomavirus 
type 18 modulates differentiation-dependent viral DNA amplification and 
late gene expression. Virology, 2007. 362(2): p. 453-60. 
41. Sanders, C.M. and A. Stenlund, Mechanism and requirements for bovine 
papillomavirus, type 1, E1 initiator complex assembly promoted by the E2 
transcription factor bound to distal sites. J Biol Chem, 2001. 276(26): p. 
23689-99. 
42. Ustav, M. and A. Stenlund, Transient replication of BPV-1 requires two 
viral polypeptides encoded by the E1 and E2 open reading frames. EMBO 
J, 1991. 10(2): p. 449-57. 
43. Ustav, M., et al., Identification of the origin of replication of bovine 
papillomavirus and characterization of the viral origin recognition factor 
E1. EMBO J, 1991. 10(13): p. 4321-9. 
44. Thomas, J.T., et al., Human papillomavirus type 31 oncoproteins E6 and 
E7 are required for the maintenance of episomes during the viral life cycle 
in normal human keratinocytes. Proc Natl Acad Sci U S A, 1999. 96(15): 
p. 8449-54. 
45. Park, R.B. and E.J. Androphy, Genetic analysis of high-risk e6 in episomal 
maintenance of human papillomavirus genomes in primary human 
keratinocytes. J Virol, 2002. 76(22): p. 11359-64. 
46. Bergvall, M., T. Melendy, and J. Archambault, The E1 proteins. Virology, 
2013. 445(1-2): p. 35-56. 
   130 
47. Castro-Munoz, L.J., et al., The Human Papillomavirus (HPV) E1 protein 
regulates the expression of cellular genes involved in immune response. 
Sci Rep, 2019. 9(1): p. 13620. 
48. Cueille, N., et al., Functional interaction between the bovine 
papillomavirus virus type 1 replicative helicase E1 and cyclin E-Cdk2. J 
Virol, 1998. 72(9): p. 7255-62. 
49. Ma, T., et al., Interaction between cyclin-dependent kinases and human 
papillomavirus replication-initiation protein E1 is required for efficient viral 
replication. Proc Natl Acad Sci U S A, 1999. 96(2): p. 382-7. 
50. Deng, W., et al., Cyclin/CDK regulates the nucleocytoplasmic localization 
of the human papillomavirus E1 DNA helicase. J Virol, 2004. 78(24): p. 
13954-65. 
51. Fradet-Turcotte, A., et al., Nuclear export of human papillomavirus type 31 
E1 is regulated by Cdk2 phosphorylation and required for viral genome 
maintenance. J Virol, 2010. 84(22): p. 11747-60. 
52. Hsu, C.Y., F. Mechali, and C. Bonne-Andrea, Nucleocytoplasmic shuttling 
of bovine papillomavirus E1 helicase downregulates viral DNA replication 
in S phase. J Virol, 2007. 81(1): p. 384-94. 
53. Yu, J.H., et al., Mitogen-activated protein kinases activate the nuclear 
localization sequence of human papillomavirus type 11 E1 DNA helicase 
to promote efficient nuclear import. J Virol, 2007. 81(10): p. 5066-78. 
54. Bian, X.L., et al., Nuclear import of bovine papillomavirus type 1 E1 protein 
is mediated by multiple alpha importins and is negatively regulated by 
   131 
phosphorylation near a nuclear localization signal. J Virol, 2007. 81(6): p. 
2899-908. 
55. Whelan, F., et al., A flexible brace maintains the assembly of a hexameric 
replicative helicase during DNA unwinding. Nucleic Acids Res, 2012. 
40(5): p. 2271-83. 
56. Amin, A.A., et al., Identification of domains of the HPV11 E1 protein 
required for DNA replication in vitro. Virology, 2000. 272(1): p. 137-50. 
57. Enemark, E.J. and L. Joshua-Tor, Mechanism of DNA translocation in a 
replicative hexameric helicase. Nature, 2006. 442(7100): p. 270-5. 
58. Dixon, E.P., et al., The E1 helicase of human papillomavirus type 11 binds 
to the origin of replication with low sequence specificity. Virology, 2000. 
270(2): p. 345-57. 
59. Sedman, J. and A. Stenlund, Co-operative interaction between the initiator 
E1 and the transcriptional activator E2 is required for replicator specific 
DNA replication of bovine papillomavirus in vivo and in vitro. EMBO J, 
1995. 14(24): p. 6218-28. 
60. Sedman, T., J. Sedman, and A. Stenlund, Binding of the E1 and E2 
proteins to the origin of replication of bovine papillomavirus. J Virol, 1997. 
71(4): p. 2887-96. 
61. Titolo, S., et al., Characterization of the minimal DNA binding domain of 
the human papillomavirus e1 helicase: fluorescence anisotropy studies 
and characterization of a dimerization-defective mutant protein. J Virol, 
2003. 77(9): p. 5178-91. 
   132 
62. Yang, L., et al., Activation of BPV-1 replication in vitro by the transcription 
factor E2. Nature, 1991. 353(6345): p. 628-32. 
63. Leng, X., J.H. Ludes-Meyers, and V.G. Wilson, Isolation of an amino-
terminal region of bovine papillomavirus type 1 E1 protein that retains 
origin binding and E2 interaction capacity. J Virol, 1997. 71(1): p. 848-52. 
64. Muller, F. and M. Sapp, Domains of the E1 protein of human 
papillomavirus type 33 involved in binding to the E2 protein. Virology, 
1996. 219(1): p. 247-56. 
65. Sarafi, T.R. and A.A. McBride, Domains of the BPV-1 E1 replication 
protein required for origin-specific DNA binding and interaction with the E2 
transactivator. Virology, 1995. 211(2): p. 385-96. 
66. Yasugi, T., et al., Mapping and characterization of the interaction domains 
of human papillomavirus type 16 E1 and E2 proteins. J Virol, 1997. 71(2): 
p. 891-9. 
67. Mohr, I.J., et al., Targeting the E1 replication protein to the papillomavirus 
origin of replication by complex formation with the E2 transactivator. 
Science, 1990. 250(4988): p. 1694-9. 
68. Bonne-Andrea, C., et al., Bovine papillomavirus type 1 DNA replication: 
the transcriptional activator E2 acts in vitro as a specificity factor. J Virol, 
1997. 71(9): p. 6805-15. 
69. Stenlund, A., E1 initiator DNA binding specificity is unmasked by selective 
inhibition of non-specific DNA binding. EMBO J, 2003. 22(4): p. 954-63. 
   133 
70. Lusky, M., J. Hurwitz, and Y.S. Seo, Cooperative assembly of the bovine 
papilloma virus E1 and E2 proteins on the replication origin requires an 
intact E2 binding site. J Biol Chem, 1993. 268(21): p. 15795-803. 
71. Lusky, M., J. Hurwitz, and Y.S. Seo, The bovine papillomavirus E2 protein 
modulates the assembly of but is not stably maintained in a replication-
competent multimeric E1-replication origin complex. Proc Natl Acad Sci U 
S A, 1994. 91(19): p. 8895-9. 
72. Chen, G. and A. Stenlund, Characterization of the DNA-binding domain of 
the bovine papillomavirus replication initiator E1. J Virol, 1998. 72(4): p. 
2567-76. 
73. Sanders, C.M. and A. Stenlund, Recruitment and loading of the E1 initiator 
protein: an ATP-dependent process catalysed by a transcription factor. 
EMBO J, 1998. 17(23): p. 7044-55. 
74. Enemark, E.J., et al., Crystal structure of the DNA binding domain of the 
replication initiation protein E1 from papillomavirus. Mol Cell, 2000. 6(1): p. 
149-58. 
75. Enemark, E.J., A. Stenlund, and L. Joshua-Tor, Crystal structures of two 
intermediates in the assembly of the papillomavirus replication initiation 
complex. EMBO J, 2002. 21(6): p. 1487-96. 
76. Sedman, J. and A. Stenlund, The initiator protein E1 binds to the bovine 
papillomavirus origin of replication as a trimeric ring-like structure. EMBO 
J, 1996. 15(18): p. 5085-92. 
   134 
77. Park, P., et al., The cellular DNA polymerase alpha-primase is required for 
papillomavirus DNA replication and associates with the viral E1 helicase. 
Proc Natl Acad Sci U S A, 1994. 91(18): p. 8700-4. 
78. Loo, Y.M. and T. Melendy, Recruitment of replication protein A by the 
papillomavirus E1 protein and modulation by single-stranded DNA. J Virol, 
2004. 78(4): p. 1605-15. 
79. McBride, A.A., The papillomavirus E2 proteins. Virology, 2013. 445(1-2): 
p. 57-79. 
80. Melendy, T., J. Sedman, and A. Stenlund, Cellular factors required for 
papillomavirus DNA replication. J Virol, 1995. 69(12): p. 7857-67. 
81. Bastien, N. and A.A. McBride, Interaction of the papillomavirus E2 protein 
with mitotic chromosomes. Virology, 2000. 270(1): p. 124-34. 
82. Ilves, I., S. Kivi, and M. Ustav, Long-term episomal maintenance of bovine 
papillomavirus type 1 plasmids is determined by attachment to host 
chromosomes, which Is mediated by the viral E2 protein and its binding 
sites. J Virol, 1999. 73(5): p. 4404-12. 
83. Lehman, C.W. and M.R. Botchan, Segregation of viral plasmids depends 
on tethering to chromosomes and is regulated by phosphorylation. Proc 
Natl Acad Sci U S A, 1998. 95(8): p. 4338-43. 
84. Skiadopoulos, M.H. and A.A. McBride, Bovine papillomavirus type 1 
genomes and the E2 transactivator protein are closely associated with 
mitotic chromatin. J Virol, 1998. 72(3): p. 2079-88. 
   135 
85. Parish, J.L., et al., ChlR1 is required for loading papillomavirus E2 onto 
mitotic chromosomes and viral genome maintenance. Mol Cell, 2006. 
24(6): p. 867-76. 
86. McBride, A.A., J.C. Byrne, and P.M. Howley, E2 polypeptides encoded by 
bovine papillomavirus type 1 form dimers through the common carboxyl-
terminal domain: transactivation is mediated by the conserved amino-
terminal domain. Proc Natl Acad Sci U S A, 1989. 86(2): p. 510-4. 
87. Giri, I. and M. Yaniv, Structural and mutational analysis of E2 trans-
activating proteins of papillomaviruses reveals three distinct functional 
domains. EMBO J, 1988. 7(9): p. 2823-9. 
88. Gauthier, J.M., J. Dillner, and M. Yaniv, Structural analysis of the human 
papillomavirus type 16-E2 transactivator with antipeptide antibodies 
reveals a high mobility region linking the transactivation and the DNA-
binding domains. Nucleic Acids Res, 1991. 19(25): p. 7073-9. 
89. Prakash, S.S., et al., Amino acids necessary for DNA contact and 
dimerization imply novel motifs in the papillomavirus E2 trans-activator. 
Genes Dev, 1992. 6(1): p. 105-16. 
90. Hubbert, N.L., et al., Bovine papilloma virus-transformed cells contain 
multiple E2 proteins. Proc Natl Acad Sci U S A, 1988. 85(16): p. 5864-8. 
91. Hegde, R.S. and E.J. Androphy, Crystal structure of the E2 DNA-binding 
domain from human papillomavirus type 16: implications for its DNA 
binding-site selection mechanism. J Mol Biol, 1998. 284(5): p. 1479-89. 
   136 
92. Mok, Y.K., et al., Equilibrium dissociation and unfolding of the dimeric 
human papillomavirus strain-16 E2 DNA-binding domain. Protein Sci, 
1996. 5(2): p. 310-9. 
93. Dostatni, N., F. Thierry, and M. Yaniv, A dimer of BPV-1 E2 containing a 
protease resistant core interacts with its DNA target. EMBO J, 1988. 
7(12): p. 3807-16. 
94. Moskaluk, C.A. and D. Bastia, The bovine papillomavirus type 1 
transcriptional activator E2 protein binds to its DNA recognition sequence 
as a dimer. Virology, 1989. 169(1): p. 236-8. 
95. Kurg, R., et al., Characterization of the functional activities of the bovine 
papillomavirus type 1 E2 protein single-chain heterodimers. J Virol, 2006. 
80(22): p. 11218-25. 
96. Kurg, R., et al., Bovine papillomavirus type 1 E2 protein heterodimer is 
functional in papillomavirus DNA replication in vivo. Virology, 2009. 
386(2): p. 353-9. 
97. Kurg, R., et al., Human papillomavirus E2 protein with single activation 
domain initiates HPV18 genome replication, but is not sufficient for long-
term maintenance of virus genome. Virology, 2010. 408(2): p. 159-66. 
98. Laanevali, A., et al., E2 protein is the major determinant of specificity at 
the human papillomavirus origin of replication. PLoS One, 2019. 14(10): p. 
e0224334. 
   137 
99. Androphy, E.J., D.R. Lowy, and J.T. Schiller, Bovine papillomavirus E2 
trans-activating gene product binds to specific sites in papillomavirus 
DNA. Nature, 1987. 325(6099): p. 70-3. 
100. Hawley-Nelson, P., et al., The specific DNA recognition sequence of the 
bovine papillomavirus E2 protein is an E2-dependent enhancer. EMBO J, 
1988. 7(2): p. 525-31. 
101. Moskaluk, C. and D. Bastia, The E2 "gene" of bovine papillomavirus 
encodes an enhancer-binding protein. Proc Natl Acad Sci U S A, 1987. 
84(5): p. 1215-8. 
102. Sanders, C.M. and A. Stenlund, Transcription factor-dependent loading of 
the E1 initiator reveals modular assembly of the papillomavirus origin 
melting complex. J Biol Chem, 2000. 275(5): p. 3522-34. 
103. Stenlund, A., Initiation of DNA replication: lessons from viral initiator 
proteins. Nat Rev Mol Cell Biol, 2003. 4(10): p. 777-85. 
104. Li, R. and M.R. Botchan, Acidic transcription factors alleviate nucleosome-
mediated repression of DNA replication of bovine papillomavirus type 1. 
Proc Natl Acad Sci U S A, 1994. 91(15): p. 7051-5. 
105. Lee, A.Y. and C.M. Chiang, Chromatin adaptor Brd4 modulates E2 
transcription activity and protein stability. J Biol Chem, 2009. 284(5): p. 
2778-86. 
106. Kumar, R.A., et al., Interaction of papillomavirus E2 protein with the Brm 
chromatin remodeling complex leads to enhanced transcriptional 
activation. J Virol, 2007. 81(5): p. 2213-20. 
   138 
107. Hou, S.Y., et al., Alleviation of human papillomavirus E2-mediated 
transcriptional repression via formation of a TATA binding protein (or 
TFIID)-TFIIB-RNA polymerase II-TFIIF preinitiation complex. Mol Cell Biol, 
2000. 20(1): p. 113-25. 
108. Tan, S.H., et al., The human papillomavirus type 16 E2 transcription factor 
binds with low cooperativity to two flanking sites and represses the E6 
promoter through displacement of Sp1 and TFIID. J Virol, 1994. 68(10): p. 
6411-20. 
109. Lambert, P.F., B.A. Spalholz, and P.M. Howley, A transcriptional repressor 
encoded by BPV-1 shares a common carboxy-terminal domain with the 
E2 transactivator. Cell, 1987. 50(1): p. 69-78. 
110. Lim, D.A., et al., Competition for DNA binding sites between the short and 
long forms of E2 dimers underlies repression in bovine papillomavirus type 
1 DNA replication control. J Virol, 1998. 72(3): p. 1931-40. 
111. Monini, P., I.L. Blitz, and E. Cassai, Cooperative DNA binding of the 
bovine papillomavirus E2 transcriptional activator is antagonized by 
truncated E2 polypeptides. J Virol, 1993. 67(9): p. 5668-76. 
112. Dreer, M., S. van de Poel, and F. Stubenrauch, Control of viral replication 
and transcription by the papillomavirus E8^E2 protein. Virus Res, 2017. 
231: p. 96-102. 
113. Powell, M.L., et al., NCoR1 mediates papillomavirus E8;E2C 
transcriptional repression. J Virol, 2010. 84(9): p. 4451-60. 
   139 
114. Antson, A.A., et al., Structure of the intact transactivation domain of the 
human papillomavirus E2 protein. Nature, 2000. 403(6771): p. 805-9. 
115. Bussiere, D.E., et al., Structure of the E2 DNA-binding domain from 
human papillomavirus serotype 31 at 2.4 A. Acta Crystallogr D Biol 
Crystallogr, 1998. 54(Pt 6 Pt 2): p. 1367-76. 
116. Bernard, B.A., et al., The human papillomavirus type 18 (HPV18) E2 gene 
product is a repressor of the HPV18 regulatory region in human 
keratinocytes. J Virol, 1989. 63(10): p. 4317-24. 
117. Schwarz, E., et al., Structure and transcription of human papillomavirus 
sequences in cervical carcinoma cells. Nature, 1985. 314(6006): p. 111-4. 
118. Thierry, F. and P.M. Howley, Functional analysis of E2-mediated 
repression of the HPV18 P105 promoter. New Biol, 1991. 3(1): p. 90-100. 
119. Romanczuk, H. and P.M. Howley, Disruption of either the E1 or the E2 
regulatory gene of human papillomavirus type 16 increases viral 
immortalization capacity. Proc Natl Acad Sci U S A, 1992. 89(7): p. 3159-
63. 
120. Romanczuk, H., F. Thierry, and P.M. Howley, Mutational analysis of cis 
elements involved in E2 modulation of human papillomavirus type 16 P97 
and type 18 P105 promoters. J Virol, 1990. 64(6): p. 2849-59. 
121. Narisawa-Saito, M. and T. Kiyono, Basic mechanisms of high-risk human 
papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. 
Cancer Sci, 2007. 98(10): p. 1505-11. 
   140 
122. Aksoy, P., E.Y. Gottschalk, and P.I. Meneses, HPV entry into cells. Mutat 
Res Rev Mutat Res, 2017. 772: p. 13-22. 
123. Zhang, P., et al., Cell-penetrating peptide inhibits retromer-mediated 
human papillomavirus trafficking during virus entry. Proc Natl Acad Sci U 
S A, 2020. 117(11): p. 6121-6128. 
124. DiGiuseppe, S., et al., Incoming human papillomavirus type 16 genome 
resides in a vesicular compartment throughout mitosis. Proc Natl Acad Sci 
U S A, 2016. 113(22): p. 6289-94. 
125. Aydin, I., et al., Large scale RNAi reveals the requirement of nuclear 
envelope breakdown for nuclear import of human papillomaviruses. PLoS 
Pathog, 2014. 10(5): p. e1004162. 
126. Pyeon, D., et al., Establishment of human papillomavirus infection requires 
cell cycle progression. PLoS Pathog, 2009. 5(2): p. e1000318. 
127. Wang, J.W. and R.B. Roden, L2, the minor capsid protein of 
papillomavirus. Virology, 2013. 445(1-2): p. 175-86. 
128. Day, P.M., et al., The papillomavirus minor capsid protein, L2, induces 
localization of the major capsid protein, L1, and the viral 
transcription/replication protein, E2, to PML oncogenic domains. J Virol, 
1998. 72(1): p. 142-50. 
129. Day, P.M., et al., Establishment of papillomavirus infection is enhanced by 
promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S 
A, 2004. 101(39): p. 14252-7. 
   141 
130. McBride, A.A., Mechanisms and strategies of papillomavirus replication. 
Biol Chem, 2017. 398(8): p. 919-927. 
131. Lace, M.J., et al., Functional mapping of the human papillomavirus type 16 
E1 cistron. J Virol, 2008. 82(21): p. 10724-34. 
132. Hoffmann, R., et al., Different modes of human papillomavirus DNA 
replication during maintenance. J Virol, 2006. 80(9): p. 4431-9. 
133. Peh, W.L., et al., Life cycle heterogeneity in animal models of human 
papillomavirus-associated disease. J Virol, 2002. 76(20): p. 10401-16. 
134. Kajitani, N., et al., Productive Lifecycle of Human Papillomaviruses that 
Depends Upon Squamous Epithelial Differentiation. Front Microbiol, 2012. 
3: p. 152. 
135. Bristol, M.L., D. Das, and I.M. Morgan, Why Human Papillomaviruses 
Activate the DNA Damage Response (DDR) and How Cellular and Viral 
Replication Persists in the Presence of DDR Signaling. Viruses, 2017. 
9(10). 
136. Moody, C.A. and L.A. Laimins, Human papillomaviruses activate the ATM 
DNA damage pathway for viral genome amplification upon differentiation. 
PLoS Pathog, 2009. 5(10): p. e1000605. 
137. Anacker, D.C., et al., HPV31 utilizes the ATR-Chk1 pathway to maintain 
elevated RRM2 levels and a replication-competent environment in 
differentiating Keratinocytes. Virology, 2016. 499: p. 383-396. 
138. Hong, S., et al., STAT-5 Regulates Transcription of the Topoisomerase 
IIbeta-Binding Protein 1 (TopBP1) Gene To Activate the ATR Pathway 
   142 
and Promote Human Papillomavirus Replication. mBio, 2015. 6(6): p. 
e02006-15. 
139. Wallace, N.A., Catching HPV in the Homologous Recombination Cookie 
Jar. Trends Microbiol, 2020. 28(3): p. 191-201. 
140. Li, X. and W.D. Heyer, Homologous recombination in DNA repair and 
DNA damage tolerance. Cell Res, 2008. 18(1): p. 99-113. 
141. Chappell, W.H., et al., Homologous Recombination Repair Factors Rad51 
and BRCA1 Are Necessary for Productive Replication of Human 
Papillomavirus 31. J Virol, 2015. 90(5): p. 2639-52. 
142. Khanal, S. and D.A. Galloway, High-risk human papillomavirus oncogenes 
disrupt the Fanconi anemia DNA repair pathway by impairing localization 
and de-ubiquitination of FancD2. PLoS Pathog, 2019. 15(2): p. e1007442. 
143. Mehta, K., et al., Human papillomaviruses activate and recruit SMC1 
cohesin proteins for the differentiation-dependent life cycle through 
association with CTCF insulators. PLoS Pathog, 2015. 11(4): p. 
e1004763. 
144. Anacker, D.C., et al., Productive replication of human papillomavirus 31 
requires DNA repair factor Nbs1. J Virol, 2014. 88(15): p. 8528-44. 
145. Uhlmann, F., SMC complexes: from DNA to chromosomes. Nat Rev Mol 
Cell Biol, 2016. 17(7): p. 399-412. 
146. Jeppsson, K., et al., The maintenance of chromosome structure: 
positioning and functioning of SMC complexes. Nat Rev Mol Cell Biol, 
2014. 15(9): p. 601-14. 
   143 
147. Aragon, L., The Smc5/6 Complex: New and Old Functions of the 
Enigmatic Long-Distance Relative. Annu Rev Genet, 2018. 52: p. 89-107. 
148. Sergeant, J., et al., Composition and architecture of the 
Schizosaccharomyces pombe Rad18 (Smc5-6) complex. Mol Cell Biol, 
2005. 25(1): p. 172-84. 
149. Alt, A., et al., Specialized interfaces of Smc5/6 control hinge stability and 
DNA association. Nat Commun, 2017. 8: p. 14011. 
150. Palecek, J., et al., The Smc5-Smc6 DNA repair complex. bridging of the 
Smc5-Smc6 heads by the KLEISIN, Nse4, and non-Kleisin subunits. J Biol 
Chem, 2006. 281(48): p. 36952-9. 
151. Zabrady, K., et al., Chromatin association of the SMC5/6 complex is 
dependent on binding of its NSE3 subunit to DNA. Nucleic Acids Res, 
2016. 44(3): p. 1064-79. 
152. Pebernard, S., et al., Nse1 RING-like domain supports functions of the 
Smc5-Smc6 holocomplex in genome stability. Mol Biol Cell, 2008. 19(10): 
p. 4099-109. 
153. Taylor, E.M., et al., Identification of the proteins, including MAGEG1, that 
make up the human SMC5-6 protein complex. Mol Cell Biol, 2008. 28(4): 
p. 1197-206. 
154. Duan, X., et al., Structural and functional insights into the roles of the 
Mms21 subunit of the Smc5/6 complex. Mol Cell, 2009. 35(5): p. 657-68. 
155. Potts, P.R. and H. Yu, Human MMS21/NSE2 is a SUMO ligase required 
for DNA repair. Mol Cell Biol, 2005. 25(16): p. 7021-32. 
   144 
156. Andrews, E.A., et al., Nse2, a component of the Smc5-6 complex, is a 
SUMO ligase required for the response to DNA damage. Mol Cell Biol, 
2005. 25(1): p. 185-96. 
157. Pebernard, S., et al., Localization of Smc5/6 to centromeres and 
telomeres requires heterochromatin and SUMO, respectively. EMBO J, 
2008. 27(22): p. 3011-23. 
158. Zapatka, M., et al., Sumoylation of Smc5 Promotes Error-free Bypass at 
Damaged Replication Forks. Cell Rep, 2019. 29(10): p. 3160-3172 e4. 
159. Gallego-Paez, L.M., et al., Smc5/6-mediated regulation of replication 
progression contributes to chromosome assembly during mitosis in human 
cells. Mol Biol Cell, 2014. 25(2): p. 302-17. 
160. Kegel, A., et al., Chromosome length influences replication-induced 
topological stress. Nature, 2011. 471(7338): p. 392-6. 
161. Lindroos, H.B., et al., Chromosomal association of the Smc5/6 complex 
reveals that it functions in differently regulated pathways. Mol Cell, 2006. 
22(6): p. 755-67. 
162. Raschle, M., et al., DNA repair. Proteomics reveals dynamic assembly of 
repair complexes during bypass of DNA cross-links. Science, 2015. 
348(6234): p. 1253671. 
163. Decorsiere, A., et al., Hepatitis B virus X protein identifies the Smc5/6 
complex as a host restriction factor. Nature, 2016. 531(7594): p. 386-9. 
   145 
164. Xu, W., et al., PJA1 Coordinates with the SMC5/6 Complex To Restrict 
DNA Viruses and Episomal Genes in an Interferon-Independent Manner. J 
Virol, 2018. 92(22). 
165. Wu, N. and H. Yu, The Smc complexes in DNA damage response. Cell 
Biosci, 2012. 2: p. 5. 
166. Kanno, T., D.G. Berta, and C. Sjogren, The Smc5/6 Complex Is an ATP-
Dependent Intermolecular DNA Linker. Cell Rep, 2015. 12(9): p. 1471-82. 
167. Potts, P.R., The Yin and Yang of the MMS21-SMC5/6 SUMO ligase 
complex in homologous recombination. DNA Repair (Amst), 2009. 8(4): p. 
499-506. 
168. Murphy, C.M., et al., Hepatitis B Virus X Protein Promotes Degradation of 
SMC5/6 to Enhance HBV Replication. Cell Rep, 2016. 16(11): p. 2846-54. 
169. Niu, C., et al., The Smc5/6 Complex Restricts HBV when Localized to 
ND10 without Inducing an Innate Immune Response and Is Counteracted 
by the HBV X Protein Shortly after Infection. PLoS One, 2017. 12(1): p. 
e0169648. 
170. Wu, S.Y., et al., Brd4 links chromatin targeting to HPV transcriptional 
silencing. Genes Dev, 2006. 20(17): p. 2383-96. 
171. Jang, M.K., et al., A proteomic approach to discover and compare 
interacting partners of papillomavirus E2 proteins from diverse 
phylogenetic groups. Proteomics, 2015. 15(12): p. 2038-50. 
   146 
172. Bentley, P., et al., The SMC5/6 Complex Interacts with the Papillomavirus 
E2 Protein and Influences Maintenance of Viral Episomal DNA. J Virol, 
2018. 92(15). 
173. Bentley, P., et al., The SMC5/6 complex interacts with the papillomavirus 
E2 protein and influences maintenance of viral episomal DNA. J Virol, 
2018. 
174. DeSmet, M., et al., Phosphorylation of a Conserved Tyrosine in the 
Papillomavirus E2 Protein Regulates Brd4 Binding and Viral Replication. J 
Virol, 2019. 93(10). 
175. DeSmet, M., et al., The Replicative Consequences of Papillomavirus E2 
Protein Binding to the Origin Replication Factor ORC2. PLoS Pathog, 
2016. 12(10): p. e1005934. 
176. Paris, C., et al., CCCTC-binding factor recruitment to the early region of 
the human papillomavirus 18 genome regulates viral oncogene 
expression. J Virol, 2015. 89(9): p. 4770-85. 
177. Choo, Y.S. and Z. Zhang, Detection of protein ubiquitination. J Vis Exp, 
2009(30). 
178. Sambrook, J. and D.W. Russell, Purification of nucleic acids by extraction 
with phenol:chloroform. CSH Protoc, 2006. 2006(1). 
179. Song, C., S. Zhang, and H. Huang, Choosing a suitable method for the 
identification of replication origins in microbial genomes. Front Microbiol, 
2015. 6: p. 1049. 
   147 
180. Murphy, C.M., et al., Hepatitis B Virus X Protein Promotes Degradation of 
SMC5/6 to Enhance HBV Replication. Cell Rep, 2016. 16(11): p. 2846-
2854. 
181. Niu, C., et al., The Smc5/6 Complex Restricts HBV when Localized to 
ND10 without Inducing an Innate Immune Response and Is Counteracted 
by the HBV X Protein Shortly after Infection. PLoS One, 2017. 12(1): p. 
e0169648. 
182. McKinney, C.C., K.L. Hussmann, and A.A. McBride, The Role of the DNA 
Damage Response throughout the Papillomavirus Life Cycle. Viruses, 
2015. 7(5): p. 2450-69. 
183. Vosa, L., et al., Identification and analysis of papillomavirus E2 protein 
binding sites in the human genome. J Virol, 2012. 86(1): p. 348-57. 
184. Jang, M.K., D. Kwon, and A.A. McBride, Papillomavirus E2 proteins and 
the host BRD4 protein associate with transcriptionally active cellular 
chromatin. J Virol, 2009. 83(6): p. 2592-600. 
185. Ramirez-Salazar, E., et al., HPV16 E2 could act as down-regulator in 
cellular genes implicated in apoptosis, proliferation and cell differentiation. 
Virol J, 2011. 8: p. 247. 
186. Stepp, W.H., J.M. Meyers, and A.A. McBride, Sp100 provides intrinsic 
immunity against human papillomavirus infection. mBio, 2013. 4(6): p. 
e00845-13. 
   148 
187. Venegas, A.B., et al., Inducible Degradation of the Human SMC5/6 
Complex Reveals an Essential Role Only during Interphase. Cell Rep, 
2020. 31(3): p. 107533. 
188. Buck, C.B., et al., Maturation of papillomavirus capsids. J Virol, 2005. 
79(5): p. 2839-46. 
189. Buck, C.B., et al., Efficient intracellular assembly of papillomaviral vectors. 
J Virol, 2004. 78(2): p. 751-7. 
190. Pyeon, D., P.F. Lambert, and P. Ahlquist, Production of infectious human 
papillomavirus independently of viral replication and epithelial cell 
differentiation. Proc Natl Acad Sci U S A, 2005. 102(26): p. 9311-6. 
191. Bienkowska-Haba, M., et al., A new cell culture model to genetically 
dissect the complete human papillomavirus life cycle. PLoS Pathog, 2018. 
14(3): p. e1006846. 
192. Richards, R.M., et al., Cleavage of the papillomavirus minor capsid 
protein, L2, at a furin consensus site is necessary for infection. Proc Natl 
Acad Sci U S A, 2006. 103(5): p. 1522-7. 
193. Day, P.M., et al., Identification of a role for the trans-Golgi network in 
human papillomavirus 16 pseudovirus infection. J Virol, 2013. 87(7): p. 
3862-70. 
194. Lancaster, W.D., C. Olson, and W. Meinke, Bovine papilloma virus: 
presence of virus-specific DNA sequences in naturally occurring equine 
tumors. Proc Natl Acad Sci U S A, 1977. 74(2): p. 524-8. 
   149 
195. Conway, M.J. and C. Meyers, Replication and assembly of human 
papillomaviruses. J Dent Res, 2009. 88(4): p. 307-17. 
196. Wang, J.W., et al., Preparation and properties of a papillomavirus 
infectious intermediate and its utility for neutralization studies. Virology, 
2014. 449: p. 304-16. 
197. Culp, T.D., L.R. Budgeon, and N.D. Christensen, Human papillomaviruses 
bind a basal extracellular matrix component secreted by keratinocytes 
which is distinct from a membrane-associated receptor. Virology, 2006. 
347(1): p. 147-59. 
198. Day, P.M., et al., A human papillomavirus (HPV) in vitro neutralization 
assay that recapitulates the in vitro process of infection provides a 
sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine 
Immunol, 2012. 19(7): p. 1075-82. 
199. Cardone, G., et al., Maturation of the human papillomavirus 16 capsid. 
mBio, 2014. 5(4): p. e01104-14. 
200. Schowalter, R.M., D.V. Pastrana, and C.B. Buck, Glycosaminoglycans 
and sialylated glycans sequentially facilitate Merkel cell polyomavirus 
infectious entry. PLoS Pathog, 2011. 7(7): p. e1002161. 
201. Buck, C.B., et al., Carrageenan is a potent inhibitor of papillomavirus 
infection. PLoS Pathog, 2006. 2(7): p. e69. 
202. Patterson, N.A., J.L. Smith, and M.A. Ozbun, Human papillomavirus type 
31b infection of human keratinocytes does not require heparan sulfate. J 
Virol, 2005. 79(11): p. 6838-47. 
   150 
203. Nassal, M., HBV cccDNA: viral persistence reservoir and key obstacle for 
a cure of chronic hepatitis B. Gut, 2015. 64(12): p. 1972-84. 
204. Sun, L., et al., Cyclic GMP-AMP synthase is a cytosolic DNA sensor that 
activates the type I interferon pathway. Science, 2013. 339(6121): p. 786-
91. 
205. Langereis, M.A., et al., Knockout of cGAS and STING Rescues Virus 
Infection of Plasmid DNA-Transfected Cells. J Virol, 2015. 89(21): p. 
11169-73. 
206. Martinez, M.G., et al., Can we cure hepatitis B virus with novel direct-
acting antivirals? Liver Int, 2020. 40 Suppl 1: p. 27-34. 
207. Breiding, D.E., et al., Functional interaction of a novel cellular protein with 
the papillomavirus E2 transactivation domain. Mol Cell Biol, 1997. 17(12): 
p. 7208-19. 
208. Wu, M.H., et al., Human papillomavirus E2 protein associates with nuclear 
receptors to stimulate nuclear receptor- and E2-dependent transcriptional 
activations in human cervical carcinoma cells. Int J Biochem Cell Biol, 
2007. 39(2): p. 413-25. 
209. Kim, J., et al., BRCA1 associates with human papillomavirus type 18 E2 
and stimulates E2-dependent transcription. Biochem Biophys Res 
Commun, 2003. 305(4): p. 1008-16. 
210. Schweiger, M.R., J. You, and P.M. Howley, Bromodomain protein 4 
mediates the papillomavirus E2 transcriptional activation function. J Virol, 
2006. 80(9): p. 4276-85. 
   151 
211. Senechal, H., et al., Amino acid substitutions that specifically impair the 
transcriptional activity of papillomavirus E2 affect binding to the long 
isoform of Brd4. Virology, 2007. 358(1): p. 10-7. 
212. Smith, J.A., et al., Genome-wide siRNA screen identifies SMCX, EP400, 
and Brd4 as E2-dependent regulators of human papillomavirus oncogene 
expression. Proc Natl Acad Sci U S A, 2010. 107(8): p. 3752-7. 
213. Lai, M.C., B.H. Teh, and W.Y. Tarn, A human papillomavirus E2 
transcriptional activator. The interactions with cellular splicing factors and 
potential function in pre-mRNA processing. J Biol Chem, 1999. 274(17): p. 
11832-41. 
214. Thierry, F. and C. Demeret, Direct activation of caspase 8 by the 
proapoptotic E2 protein of HPV18 independent of adaptor proteins. Cell 
Death Differ, 2008. 15(9): p. 1356-63. 
215. Lee, D., et al., cAMP response element-binding protein-binding protein 
binds to human papillomavirus E2 protein and activates E2-dependent 
transcription. J Biol Chem, 2000. 275(10): p. 7045-51. 
216. Bellanger, S., et al., High-risk but not low-risk HPV E2 proteins bind to the 
APC activators Cdh1 and Cdc20 and cause genomic instability. Cell 
Cycle, 2005. 4(11): p. 1608-15. 
217. Hadaschik, D., et al., The Papillomavirus E2 protein binds to and 
synergizes with C/EBP factors involved in keratinocyte differentiation. J 
Virol, 2003. 77(9): p. 5253-65. 
   152 
218. Wang, W., et al., Triggering of death receptor apoptotic signaling by 
human papillomavirus 16 E2 protein in cervical cancer cell lines is 
mediated by interaction with c-FLIP. Apoptosis, 2011. 16(1): p. 55-66. 
219. Fertey, J., et al., Interaction of the papillomavirus E8--E2C protein with the 
cellular CHD6 protein contributes to transcriptional repression. J Virol, 
2010. 84(18): p. 9505-15. 
220. Muller, M., et al., Large scale genotype comparison of human 
papillomavirus E2-host interaction networks provides new insights for e2 
molecular functions. PLoS Pathog, 2012. 8(6): p. e1002761. 
221. Johansson, C., et al., HPV-16 E2 contributes to induction of HPV-16 late 
gene expression by inhibiting early polyadenylation. EMBO J, 2012. 
31(14): p. 3212-27. 
222. Zheng, G., et al., Brd4 regulation of papillomavirus protein E2 stability. J 
Virol, 2009. 83(17): p. 8683-92. 
223. Muller, A., A. Ritzkowsky, and G. Steger, Cooperative activation of human 
papillomavirus type 8 gene expression by the E2 protein and the cellular 
coactivator p300. J Virol, 2002. 76(21): p. 11042-53. 
224. DeSmet, M., et al., Papillomavirus E2 protein is regulated by specific 
fibroblast growth factor receptors. Virology, 2018. 521: p. 62-68. 
225. Xie, F., et al., Kinase Activity of Fibroblast Growth Factor Receptor 3 
Regulates Activity of the Papillomavirus E2 Protein. J Virol, 2017. 91(20). 
   153 
226. Wu, M.H., et al., Physical and functional interactions of human 
papillomavirus E2 protein with nuclear receptor coactivators. Biochem 
Biophys Res Commun, 2007. 356(3): p. 523-8. 
227. Ammermann, I., et al., Inhibition of transcription and DNA replication by 
the papillomavirus E8-E2C protein is mediated by interaction with 
corepressor molecules. J Virol, 2008. 82(11): p. 5127-36. 
228. Bian, X.L. and V.G. Wilson, Common importin alpha specificity for 
papillomavirus E2 proteins. Virus Res, 2010. 150(1-2): p. 135-7. 
229. Gammoh, N., et al., The Mdm2 ubiquitin ligase enhances transcriptional 
activity of human papillomavirus E2. J Virol, 2009. 83(3): p. 1538-43. 
230. Rehtanz, M., et al., Direct interaction between nucleosome assembly 
protein 1 and the papillomavirus E2 proteins involved in activation of 
transcription. Mol Cell Biol, 2004. 24(5): p. 2153-68. 
231. Chang, S.W., et al., NRIP enhances HPV gene expression via interaction 
with either GR or E2. Virology, 2012. 423(1): p. 38-48. 
232. Lee, D., et al., Functional interaction between human papillomavirus type 
18 E2 and poly(ADP-ribose) polymerase 1. Oncogene, 2002. 21(38): p. 
5877-85. 
233. Lee, D., et al., Functional interaction between p/CAF and human 
papillomavirus E2 protein. J Biol Chem, 2002. 277(8): p. 6483-9. 
234. Wang, W.S., et al., Interaction between human papillomavirus type 5 E2 
and polo-like kinase 1. J Med Virol, 2009. 81(3): p. 536-44. 
   154 
235. Li, R. and M.R. Botchan, The acidic transcriptional activation domains of 
VP16 and p53 bind the cellular replication protein A and stimulate in vitro 
BPV-1 DNA replication. Cell, 1993. 73(6): p. 1207-21. 
236. Bodaghi, S., R. Jia, and Z.M. Zheng, Human papillomavirus type 16 E2 
and E6 are RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs 
with suboptimal splice sites. Virology, 2009. 386(1): p. 32-43. 
237. Bellanger, S., et al., The human papillomavirus type 18 E2 protein is a cell 
cycle-dependent target of the SCFSkp2 ubiquitin ligase. J Virol, 2010. 
84(1): p. 437-44. 
238. Cha, S. and T. Seo, hSNF5 is required for human papillomavirus E2-
driven transcriptional activation and DNA replication. Intervirology, 2011. 
54(2): p. 66-77. 
239. Strasswimmer, J., et al., Identification of survival motor neuron as a 
transcriptional activator-binding protein. Hum Mol Genet, 1999. 8(7): p. 
1219-26. 
240. Steger, G., C. Schnabel, and H.M. Schmidt, The hinge region of the 
human papillomavirus type 8 E2 protein activates the human 
p21(WAF1/CIP1) promoter via interaction with Sp1. J Gen Virol, 2002. 
83(Pt 3): p. 503-510. 
241. Carrillo, E., E. Garrido, and P. Gariglio, Specific in vitro interaction 
between papillomavirus E2 proteins and TBP-associated factors. 
Intervirology, 2004. 47(6): p. 342-9. 
   155 
242. Centeno, F., et al., TAF1 interacts with and modulates human 
papillomavirus 16 E2-dependent transcriptional regulation. Intervirology, 
2008. 51(2): p. 137-43. 
243. Enzenauer, C., et al., Interaction of human papillomavirus 8 regulatory 
proteins E2, E6 and E7 with components of the TFIID complex. 
Intervirology, 1998. 41(2-3): p. 80-90. 
244. Wang, X., et al., Tax1BP1 interacts with papillomavirus E2 and regulates 
E2-dependent transcription and stability. J Virol, 2009. 83(5): p. 2274-84. 
245. Hartley, K.A. and K.A. Alexander, Human TATA binding protein inhibits 
human papillomavirus type 11 DNA replication by antagonizing E1-E2 
protein complex formation on the viral origin of replication. J Virol, 2002. 
76(10): p. 5014-23. 
246. Massimi, P., et al., Interaction between the HPV-16 E2 transcriptional 
activator and p53. Oncogene, 1999. 18(54): p. 7748-54. 
247. Benson, J.D., R. Lawande, and P.M. Howley, Conserved interaction of the 
papillomavirus E2 transcriptional activator proteins with human and yeast 
TFIIB proteins. J Virol, 1997. 71(10): p. 8041-7. 
248. Boner, W., et al., A Functional interaction between the human 
papillomavirus 16 transcription/replication factor E2 and the DNA damage 
response protein TopBP1. J Biol Chem, 2002. 277(25): p. 22297-303. 
249. Clower, R.V., Y. Hu, and T. Melendy, Papillomavirus E2 protein interacts 
with and stimulates human topoisomerase I. Virology, 2006. 348(1): p. 13-
8. 
   156 
250. Wu, Y.C., et al., Modification of papillomavirus E2 proteins by the small 
ubiquitin-like modifier family members (SUMOs). Virology, 2008. 378(2): p. 
329-38. 
251. Mendoza-Maldonado, R., et al., Interaction of the retinoblastoma protein 
with Orc1 and its recruitment to human origins of DNA replication. PLoS 









Ph.D. Indiana University, Indianapolis, IN 46202 (2015 - 2020) 
  Microbiology & Immunology 
Cancer Biology minor 
 
M.A. Ball State University, Muncie, IN 47304 (2014 - 2015) 
  Biology 
  Dean’s Citation for Academic Excellence 
 
B.S. Ball State University, Muncie, IN 47304 (2012 - 2014) 
  Biology 
  Biotechnology Certificate 





• Characterizing the role of the SMC5/6 complex as a host             2016-20 
restriction factor of high-risk human papillomavirus 
       Primary Investigator: Dr. Elliot Androphy 
 
• Optimization of human papillomavirus-based pseudovirus          2018-20 
     techniques for efficient gene transfer 
       Primary Investigator: Dr. Elliot Androphy 
 
• Plasmodium falciparum transmission in the development of     2015 
       malaria in highland versus lowland populations in Kenya 
Primary Investigator: Dr. Chandy John 
 
• Proviral activation of latently HIV-1 infected monocytes     2015 
Primary Investigator: Dr. Quigui Yu 
 
• The role of TAL1 in T-cell acute lymphoblastic leukemia     2013-2015 
Primary Investigator: Dr. James Olesen 
 
• Quality control mechanisms of the ER translocon     2014 
Primary Investigator: Dr. Eric Rubenstein  
 
   
PUBLICATIONS 
 
Ryan T. Gibson and Elliot J. Androphy. The SMC5/6 complex represses the 
replicative program of high-risk human papillomavirus type 31. Pathogens, 2020. 
9(10). 
 
Gilson, T.D.*, Gibson, R.T.*, and Androphy, E.J. Optimization of human 
papillomavirus-based pseudovirus techniques for efficient gene transfer. Sci Rep, 
2020. 10(1): p. 15517. [*co-first author] 
 
Crowder, J.J., Geigges, M., Gibson, R.T., Fults, E.S., Buchanan, B.W., Sachs, 
N., Schink, A., Kreft, S.G., and Rubenstein, E.M. Rkr1/Ltn1 Ubiquitin Ligase-
mediated Degradation of Translationally Stalled Endoplasmic Reticulum Proteins. 
J Biol Chem, 2015. 290(30): p. 18454. 
 
Ryan T. Gibson and James B. Olesen. Development of an 
immunocytochemistry protocol for the study of TAL1 mediated apoptotic 






   
PRESENTATIONS 
 
Gibson, R.T. Elucidating the role of SMC5/6 in the life cycle of high-risk human 
papillomavirus. 2018-19. Indiana University School of Medicine. 
 
Gibson, R.T., Patel, J., Victorino, J. 2017. Think, Talk, and Study Like a 
Graduate Student. Indiana University School of Medicine. 
 
Gibson, R.T., Varberg, K., Victorino, J. 2016. Think, Talk, and Study Like a 
Graduate Student. Indiana University School of Medicine. 
 
Gibson, R.T. 2015. Suitability of αSNAP for inhibition of Staphylococcus aureus 











   
HONORS AND AWARDS 
 
• ASPiRE Grant Recipient         2015 
• Ball State University Dean’s Citation for Academic Excellence  2015 
• Ball State University Certificate of Achievement     2015 
• Ball State University Dean’s List     2012 – 2014 




• Sigma Xi International Research Society  Member        2014 – Present 
• Omicron Delta Kappa Honor Society Member         2014 – Present 
• Golden Key Honor Society Member          2014 – Present 
 
 
 
 
 
 
 
